WO2023231997A1 - 一种哒嗪类化合物、其制备方法和用途 - Google Patents
一种哒嗪类化合物、其制备方法和用途 Download PDFInfo
- Publication number
- WO2023231997A1 WO2023231997A1 PCT/CN2023/096975 CN2023096975W WO2023231997A1 WO 2023231997 A1 WO2023231997 A1 WO 2023231997A1 CN 2023096975 W CN2023096975 W CN 2023096975W WO 2023231997 A1 WO2023231997 A1 WO 2023231997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- methyl
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- -1 Pyridazine compound Chemical class 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 156
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims abstract 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 150000002367 halogens Chemical group 0.000 claims description 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 229910052736 halogen Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 201000004681 Psoriasis Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 125000004431 deuterium atom Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 description 116
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 113
- 230000015572 biosynthetic process Effects 0.000 description 104
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 description 99
- 238000001308 synthesis method Methods 0.000 description 99
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 90
- 238000005481 NMR spectroscopy Methods 0.000 description 85
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 65
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 54
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 25
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 229940125904 compound 1 Drugs 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HYWPFIXULAMLRZ-UHFFFAOYSA-N 4-bromo-1-propan-2-ylpyrazole Chemical compound CC(C)N1C=C(Br)C=N1 HYWPFIXULAMLRZ-UHFFFAOYSA-N 0.000 description 12
- 239000004698 Polyethylene Substances 0.000 description 12
- 102000015774 TYK2 Kinase Human genes 0.000 description 12
- 108010010057 TYK2 Kinase Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 11
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- KWGLUDZPAMFWJZ-UHFFFAOYSA-N 3-bromo-1-methyl-1,2,4-triazole Chemical compound CN1C=NC(Br)=N1 KWGLUDZPAMFWJZ-UHFFFAOYSA-N 0.000 description 8
- IPMSARLBJARXSC-UHFFFAOYSA-N 4-bromo-1-ethylpyrazole Chemical compound CCN1C=C(Br)C=N1 IPMSARLBJARXSC-UHFFFAOYSA-N 0.000 description 8
- DXSGAWDYWNGHGR-UHFFFAOYSA-N 4-bromo-2-(difluoromethoxy)aniline Chemical compound NC1=CC=C(Br)C=C1OC(F)F DXSGAWDYWNGHGR-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- VEQGOZCVNSMHRR-UHFFFAOYSA-N 2,2-difluorocyclopropane-1-carboxamide Chemical compound NC(=O)C1CC1(F)F VEQGOZCVNSMHRR-UHFFFAOYSA-N 0.000 description 7
- BMTRQKSIZCYODG-FIBGUPNXSA-N 4-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C([2H])([2H])([2H])C1=C(N=NC=C1)C(=O)N BMTRQKSIZCYODG-FIBGUPNXSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- IXJSDKIJPVSPKF-UHFFFAOYSA-N 4-bromo-1-methylpyrazole Chemical compound CN1C=C(Br)C=N1 IXJSDKIJPVSPKF-UHFFFAOYSA-N 0.000 description 5
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 229940124282 BMS-986165 Drugs 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 239000003777 experimental drug Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- PRDMZNDYNNMIGZ-UHFFFAOYSA-N 4-bromo-1-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC(Br)=CC=C1[N+]([O-])=O PRDMZNDYNNMIGZ-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- PHZKRDKMJHXGBR-GBXIJSLDSA-N (1s,2s)-2-fluorocyclopropane-1-carboxamide Chemical compound NC(=O)[C@@H]1C[C@@H]1F PHZKRDKMJHXGBR-GBXIJSLDSA-N 0.000 description 3
- PCWRBBLXAOCSQC-UHFFFAOYSA-N 4-bromo-1-cyclopropylpyrazole Chemical compound C1=C(Br)C=NN1C1CC1 PCWRBBLXAOCSQC-UHFFFAOYSA-N 0.000 description 3
- QLTGZJJIJOVVTA-UHFFFAOYSA-N 5-bromo-2-ethyltetrazole Chemical compound CCN1N=NC(Br)=N1 QLTGZJJIJOVVTA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- VOGSDFLJZPNWHY-UHFFFAOYSA-N 2,2-difluoroethanol Chemical compound OCC(F)F VOGSDFLJZPNWHY-UHFFFAOYSA-N 0.000 description 2
- VGBGYXBQQDJFBZ-UHFFFAOYSA-N 3-bromo-1-cyclopropyl-1,2,4-triazole Chemical compound Brc1ncn(n1)C1CC1 VGBGYXBQQDJFBZ-UHFFFAOYSA-N 0.000 description 2
- FCHSZRYGYSELEY-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethoxy)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C(OC(F)(F)F)=C1 FCHSZRYGYSELEY-UHFFFAOYSA-N 0.000 description 2
- LQEUMDCDRJXBAC-UHFFFAOYSA-N 4-bromo-1-(3,3,3-trifluoropropyl)pyrazole Chemical compound FC(F)(F)CCN1C=C(Br)C=N1 LQEUMDCDRJXBAC-UHFFFAOYSA-N 0.000 description 2
- YZFOWGPIDPASFC-UHFFFAOYSA-N 4-bromo-1-(difluoromethyl)pyrazole Chemical compound FC(F)N1C=C(Br)C=N1 YZFOWGPIDPASFC-UHFFFAOYSA-N 0.000 description 2
- MPEZKCXHVQSKLO-UHFFFAOYSA-N 5-bromo-1-methyltetrazole Chemical compound CN1N=NN=C1Br MPEZKCXHVQSKLO-UHFFFAOYSA-N 0.000 description 2
- KYRMPMCAOPMOIR-UHFFFAOYSA-N 5-ethyl-2h-tetrazole Chemical compound CCC=1N=NNN=1 KYRMPMCAOPMOIR-UHFFFAOYSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- XHYGUDGTUJPSNX-UHFFFAOYSA-N 6-bromopyridine-3-carbonitrile Chemical compound BrC1=CC=C(C#N)C=N1 XHYGUDGTUJPSNX-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LPWKFUVWWQYLOD-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-methylphenyl)pyrido[2,3]thieno[2,4-d]pyrimidin-4-one Chemical compound C1=2C(N(C)C)=CN=CC=2SC(C2=O)=C1N=CN2C1=CC=C(C)C=C1 LPWKFUVWWQYLOD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000006419 fluorocyclopropyl group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- YKEGUYTXACKXKS-IRXDYDNUSA-N tert-butyl (1s,5s)-3-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC1=NC=CC=C1OC1=NC=NC(OC2C[C@@H]3CC[C@H](N3C(=O)OC(C)(C)C)C2)=C1C YKEGUYTXACKXKS-IRXDYDNUSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- NLWYVKHISUTBMY-UHFFFAOYSA-N 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2CC2)N=C1 NLWYVKHISUTBMY-UHFFFAOYSA-N 0.000 description 1
- UGCRHVPUHAXAAE-UHFFFAOYSA-N 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(CC)C=C1B1OC(C)(C)C(C)(C)O1 UGCRHVPUHAXAAE-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- NUGZBVBZIDWZAD-UHFFFAOYSA-N 1h-pyrazole-4-carbonitrile Chemical compound N#CC=1C=NNC=1 NUGZBVBZIDWZAD-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- MIKIWDXOQIASTM-UHFFFAOYSA-N 2-(4-bromopyrazol-1-yl)acetonitrile Chemical compound BrC=1C=NN(CC#N)C=1 MIKIWDXOQIASTM-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- ANSMRNCOBLTNBO-UHFFFAOYSA-N 2-bromo-5-fluoropyrimidine Chemical compound FC1=CN=C(Br)N=C1 ANSMRNCOBLTNBO-UHFFFAOYSA-N 0.000 description 1
- BGRKDLVBPMCBJW-UHFFFAOYSA-N 2-ethyltetrazole Chemical compound CCN1N=CN=N1 BGRKDLVBPMCBJW-UHFFFAOYSA-N 0.000 description 1
- GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- VRESBNUEIKZECD-UHFFFAOYSA-N 2-methyltetrazole Chemical compound CN1N=CN=N1 VRESBNUEIKZECD-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VGWXCRGEZCMEJU-UHFFFAOYSA-N 3,3-difluorocyclobutane-1-carboxamide Chemical compound NC(=O)C1CC(F)(F)C1 VGWXCRGEZCMEJU-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IPDWEAXPUUZRBK-UHFFFAOYSA-N 3-bromo-1-ethyl-1,2,4-triazole Chemical group CCN1C=NC(Br)=N1 IPDWEAXPUUZRBK-UHFFFAOYSA-N 0.000 description 1
- ZGEVJEQMVRIEPX-UHFFFAOYSA-N 3-bromo-1-methylpyrazole Chemical compound CN1C=CC(Br)=N1 ZGEVJEQMVRIEPX-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KDEJQUNODYXYBJ-UHFFFAOYSA-N 4-(trifluoromethyl)-1h-pyrazole Chemical compound FC(F)(F)C=1C=NNC=1 KDEJQUNODYXYBJ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- ODBMLKPFRGSZSG-UHFFFAOYSA-N 4-bromo-1-(2,2,2-trifluoroethyl)pyrazole Chemical compound FC(F)(F)CN1C=C(Br)C=N1 ODBMLKPFRGSZSG-UHFFFAOYSA-N 0.000 description 1
- SJIMZWZHTDHXRI-UHFFFAOYSA-N 4-bromo-1-(2-methoxyethyl)pyrazole Chemical compound COCCN1C=C(Br)C=N1 SJIMZWZHTDHXRI-UHFFFAOYSA-N 0.000 description 1
- OPOXCQUYNYTHDA-UHFFFAOYSA-N 4-bromo-1-(trifluoromethyl)pyrazole Chemical compound FC(F)(F)N1C=C(Br)C=N1 OPOXCQUYNYTHDA-UHFFFAOYSA-N 0.000 description 1
- QVILSWLYJYMGRN-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(Br)C=C1OC(F)(F)F QVILSWLYJYMGRN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- SQTWGTRJXOVEMT-UHFFFAOYSA-N 5-bromo-1-ethyltetrazole Chemical compound CCN1N=NN=C1Br SQTWGTRJXOVEMT-UHFFFAOYSA-N 0.000 description 1
- HCLIOEQJSYROPH-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)tetrazole Chemical compound FC(F)(F)N1N=NC(Br)=N1 HCLIOEQJSYROPH-UHFFFAOYSA-N 0.000 description 1
- FTCJTCRPKDANII-UHFFFAOYSA-N 5-bromo-2-methyltetrazole Chemical compound CN1N=NC(Br)=N1 FTCJTCRPKDANII-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- IYIHPLRMCWIFFZ-UHFFFAOYSA-N 5-methylsulfonyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole Chemical compound CS(=O)(=O)N1Cc2cn[nH]c2C1 IYIHPLRMCWIFFZ-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WZCZNEGTXVXAAS-UHFFFAOYSA-N trifluoromethanol Chemical compound OC(F)(F)F WZCZNEGTXVXAAS-UHFFFAOYSA-N 0.000 description 1
- 125000005590 trimellitic acid group Chemical class 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention belongs to the field of medicine and relates to a pyridazine compound, its preparation method and use.
- Psoriasis is an autoimmune system disease. It is a chronic, relapsing, and inflammatory skin disease mediated by immunity. Its pathogenesis is complex and it cannot be completely cured at present.
- Traditional treatments for psoriasis mainly include topical treatments such as hydrotherapy, phototherapy, traditional Chinese medicine, and salicylates, as well as glucocorticoids, immunosuppressants, and retinoic acid drugs. Due to the remarkable efficacy of biological agents (mainly TNF inhibitors and IL inhibitors) and PDE4 small molecule inhibitors in recent years, they have become the main treatment drugs for psoriasis.
- Tyrosine Kinase 2 is a non-receptor tyrosine kinase that belongs to the Janus kinase (JAK) family and plays an important role in the pathogenesis of psoriasis.
- JNK Janus kinase
- Existing research believes that overactivation of part of the adaptive immune system is the core of the pathogenesis of psoriasis.
- a variety of immune cells and cytokines jointly lead to the proliferation of downstream keratinocytes, increase angiogenesis, and promote endothelial disease.
- the expression of adhesion molecules and activated immune cells infiltrate into the diseased skin, eventually forming psoriasis.
- IL-23 signaling mainly mediates related effects in cells through the TYK2-JAK2 and STAT3 pathways.
- New tyrosine kinase 2 (Tyrosine Kinase 2, TYK2) inhibitors can block receptor-stimulated activation of TYK2, thereby inhibiting the phosphorylation of STAT1 and STAT3 caused by TYK2, thereby inhibiting the pathogenesis of psoriasis.
- the present invention provides a class of pyridazine compounds, pharmaceutically acceptable salts and isotope derivatives thereof, their preparation methods, pharmaceutical compositions and their use in medicines for preventing and treating diseases related to the TYK2 signaling pathway.
- the present invention provides a compound represented by general formula (II) or a pharmaceutically acceptable salt or isotope derivative thereof,
- R 1 is -C 1-3 deuterated alkyl
- R 2 is -C 3-6 cycloalkyl, wherein the -C 3-6 cycloalkyl is optionally further selected from the group consisting of hydrogen atoms, -C 1-3 alkyl and halo Substituted by one or more substituents in the element;
- R 3 is -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy, wherein the -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy is optional Ground is further substituted with one or more substituents selected from hydrogen atoms, deuterium atoms, -C 1-3 alkyl groups and halogens;
- R 4 is a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by R a ;
- R a is -H, -CN, -CF 3 , -C 1-3 alkyl, -C 3-6 cycloalkyl or 4-6 membered heterocyclyl, wherein the -C 1-3 alkyl or -C 3-6 cycloalkyl is optionally further substituted with one or more substituents selected from hydrogen atoms, -C 1-3 alkyl and halogen.
- R 1 is -CD 3 ;
- R 2 is substituted or unsubstituted cyclopropyl
- R 3 is -OCF 3 , -O-CH 2 CF 3 , -OCHF 2 , -O-CH 2 CHF 2 , -OCH(CH 3 ) 2 or
- R a is -H, -CN, -CHF 2 , methyl, ethyl, trifluoromethyl, -CH(CH 3 ) 2 or cyclopropyl.
- R 1 is -C 1-3 deuterated alkyl
- R 2 is -C 3-6 cycloalkyl, wherein the -C 3-6 cycloalkyl is optionally further substituted with one or more selected from hydrogen atoms, -C 1-3 alkyl and halogen substituted by base;
- R 3 is -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy, wherein the -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy is optional Ground is further substituted with one or more substituents selected from hydrogen atoms, deuterium atoms, -C 1-3 alkyl groups and halogens;
- R 4 is a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by R a ;
- R a is -H, -CN, -CF 3 , -C 1-3 alkyl, -C 3-6 cycloalkyl or 4-6 membered heterocyclyl, wherein the -C 1-3 alkyl or -C 3-6 cycloalkyl is optionally further substituted with one or more substituents selected from hydrogen atoms, -C 1-3 alkyl and halogen.
- R 1 is -CD 3 ;
- R 2 is substituted or unsubstituted cyclopropyl
- R 3 is -OCF 3 , -O-CH 2 CF 3 , -OCHF 2 , -O-CH 2 CHF 2 , -OCH(CH 3 ) 2 or
- R a is -H, -CN, -CHF 2 , methyl, ethyl, trifluoromethyl, -CH(CH 3 ) 2 or cyclopropyl.
- R 1 is -C 1-3 deuterated alkyl
- R 2 is -C 3-6 cycloalkyl
- R 3 is halogen-substituted C 1-3 alkoxy
- R 4 is a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by R a ;
- R a is -H, -C 1-3 alkyl, -C 1-3 haloalkyl, -C 3-6 cycloalkyl or 4-6 membered heterocyclyl.
- R 1 is -CD 3 ;
- R 2 is cyclopropyl
- R 3 is -OCF 3 or -OCHF 2 .
- R 4 is a 5-membered heteroaryl group optionally substituted by Ra , the heteroaryl group containing 1, 2, 3 or 4 nitrogen heteroatoms.
- R 4 is
- R a is -H, methyl, ethyl, trifluoromethyl or cyclopropyl.
- R 1 is -C 1-3 deuterated alkyl
- R 2 is -C 3-6 cycloalkyl
- R 3 is -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy, wherein the -C 1-3 alkyloxy or -C 3-6 cycloalkyloxy is optional Ground is further substituted with one or more substituents selected from hydrogen atoms, deuterium atoms, -C 1-3 alkyl groups and halogens;
- R 4 is a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by R a ;
- R a is -H, -CN, -CF 3 , -C 1-3 alkyl, -C 3-6 cycloalkyl or 4-6 membered heterocyclyl, wherein the -C 1-3 alkyl or -C 3-6 cycloalkyl is optionally further substituted with one or more substituents selected from hydrogen atoms, -C 1-3 alkyl and halogen.
- R 1 is -CD 3 ;
- R 2 is cyclopropyl
- R 3 is -OCF 3 , -O-CH 2 CF 3 , -OCHF 2 , -O-CH 2 CHF 2 , -OCH(CH 3 ) 2 or
- R a is -H, -CN, -CHF 2 , methyl, ethyl, trifluoromethyl, -CH(CH 3 ) 2 or cyclopropyl.
- the compound of the present invention or a pharmaceutically acceptable salt or isotope derivative thereof is selected from the following compounds or a pharmaceutically acceptable salt or isotope derivative thereof:
- the present invention also provides a preparation method of the compound represented by general formula II, which can be Scheme 1 or Scheme 2,
- R 1 , R 2 , R 3 and R 4 are as described above.
- the present invention also provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound represented by formula II and one or more pharmaceutically acceptable carriers and/or diluents.
- the present invention also provides the use of the compound represented by Formula II or the pharmaceutical composition in the preparation of drugs for preventing and/or treating TYK2-mediated diseases.
- the TYK2-mediated disease includes an inflammatory disease or an autoimmune disease.
- the inflammatory and autoimmune diseases are psoriasis, inflammatory bowel disease, or lupus erythematosus.
- the present invention also provides methods for treating TYK2-mediated diseases, comprising administering a therapeutically effective amount of a compound of Formula II to a patient in need of such treatment.
- substituted means that any one or more hydrogens on a designated atom or group are replaced by a selected selection of the designated group, provided that the normal valence of the designated atom is not exceeded.
- 2 hydrogens on the atom are replaced.
- a stable compound or stable structure is one that is sufficiently stable to withstand isolation from the reaction mixture with useful purity and subsequent formulation into an effective therapeutic agent.
- “optionally” or “optionally” means that the subsequently described event or situation may or may not occur, and the description includes both the occurrence and non-occurrence of the event or situation.
- “Optionally substituted” refers to a group having 0, 1, 2 or more substituents. It will be understood by those skilled in the art that for any group containing one or more substituents, these groups do not introduce any substitution or substitution pattern that is stereoscopically unrealistic, synthetically unfeasible, and/or inherently unstable. .
- “optionally substituted aryl” means that the aryl group is substituted or unsubstituted, and the description includes both substituted and unsubstituted aryl groups.
- the compounds herein encompass within their scope the compounds, their pharmaceutically acceptable salts and isotopic derivatives thereof, and the compounds of the invention also encompass within their scope their stereoisomers, polymorphs, solvates and prodrug.
- stereoisomers as used herein encompass within their scope tautomers, meso, racemates, enantiomers, diastereoisomers, and mixtures thereof.
- isotopic derivative refers to a derivative of a compound in which one or more atoms are replaced by its isotopes (atoms with the same atomic number but an atomic mass or mass number different from the atomic mass or mass number that predominates in nature).
- isotopes include, but are not limited to, isotopes of hydrogen (e.g. 2 H, 3 H), isotopes of carbon (e.g. 11 C, 13 C and 14 C), isotopes of fluorine (e.g. 18 F), isotopes of nitrogen (e.g. 13 N and 15 N), oxygen isotopes (such as 15 O, 17 O and 18 O).
- Compounds of the present invention include isotopic derivatives of compounds of the present invention, for example, isotopic derivatives of compound 2
- alkyl or “alkylene” is meant to include both branched and straight chain saturated aliphatic hydrocarbon radicals having the specified number of carbon atoms.
- C 1 -C 10 alkyl (or alkylene) is meant to include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 alkyl base.
- C 1 -C 6 alkyl means an alkyl group having 1 to 6 carbon atoms. An alkyl group may be unsubstituted or substituted such that one or more of its hydrogens are replaced by another chemical group.
- alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl group), pentyl group (for example, n-pentyl group, isopentyl group, neopentyl group), hexyl group (for example, n-hexyl group, isohexyl group), etc.
- C 1-3 alkyl refers to an alkyl group containing 1 to 3 carbon atoms, specifically methyl, ethyl, n-propyl and isopropyl.
- deuterated alkyl refers to an alkyl group in which one or more hydrogens are replaced by deuterium.
- C 1-3 deuterated alkyl refers to a methyl, ethyl, n-propyl and Isopropyl, for example deuterated methyl includes CD 3 , CHD 2 , CH 2 D.
- halo refers to chlorine, bromine, fluorine and iodine.
- haloalkyl refers to a substituted alkyl group having one or more halogen substituents.
- fluoromethyl package Including CF 3 , CHF 2 , CH 2 F.
- alkyloxy refers to a substituent formed by joining an alkyl group and an oxygen atom as defined herein.
- C 1-3 alkoxy refers to an alkoxy group containing 1 to 3 carbon atoms, for example, methoxy, ethoxy, propoxy and isopropoxy.
- haloalkoxy and “halogen-substituted alkoxy” have the same meaning and refer to an alkoxy group having one or more halogen substituents.
- fluoromethoxy includes OCF3 , OCHF2 , OCH2F .
- cycloalkyl refers to a cyclized alkyl group, including a monocyclic, bicyclic or polycyclic ring system, wherein the ring of the monocyclic, bicyclic or polycyclic system does not contain an aromatic ring.
- the cycloalkyl groups may independently be unsubstituted or substituted with one or more substituents described herein.
- C 3-6 cycloalkyl refers to a cycloalkyl group containing 3 to 6 carbon atoms.
- heterocycle or “heterocyclyl” have the same meaning and refer to any ring structure (saturated, unsaturated, or aromatic) containing at least one ring heteroatom (e.g., nitrogen atom, oxygen atom, or sulfur atom) of).
- Heterocycles include "aliphatic heterocycles" and "aromatic heterocycles.”
- the heterocyclyl group is a 4-6 membered heterocyclyl group, examples of which include, but are not limited to, furyl, imidazolidinyl, imidazolinyl, imidazolyl, isoquinolinyl, thiazolyl, Isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, oxazolidinyl, oxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazole 5(4H)-keto, piperazinyl, Piperidinyl, piperidinonyl, 4-piperidinonyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl,
- aliphatic ring or “aliphatic heterocyclyl” have the same meaning and refer to heterocyclic compounds without aromatic characteristics, for example, oxetane, azetidine, pyrrolidinyl, 2H-pyrrolyl , tetrahydrofuranyl.
- aromatic heterocycle refers to heterocyclic compounds with aromatic characteristics, including single heterocyclic aryl and condensed heterocyclic Ring aromatic group.
- the monoheterocyclic aryl group can be a 5-6 membered heteroaryl group and can contain 1-4 heteroatoms, such as pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, etc.
- Typical 5-6 membered heteroaryl groups include, but are not limited to, 2- or 3-thienyl; 2- or 3-furyl; 2- or 3-pyrrolyl; 2-, 4- or 5-imidazolyl; 3 -, 4- or 5-pyrazolyl; 2-, 4- or 5-thiazolyl; 3-, 4- or 5-isothiazolyl; 2-, 4- or 5-azolyl; 3-, 4- or 5-isozolyl; 3-or 5-1,2,4-triazolyl; 4-or 5-1,2,3-triazolyl; tetrazole base; 2-, 3- or 4-pyridyl; 3- or 4-pyridazinyl; 3-, 4- or 5-pyrazinyl; 2-pyrazinyl; 2-, 4- or 5-pyrimidinyl .
- the fused heterocyclic aryl group can be a tricyclic ring or a bicyclic ring, such as benzoxazole, benzodiazole, benzothiazole, benzimidazole, benzothiophene, methylenedioxybenzene base, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran, deazapurine or indole.
- aromatic ring of "heteroaryl” may be substituted at one or more ring positions by the substituents mentioned above, such as halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxy Carbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, alkylaminocarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl , alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkyl arylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
- pharmaceutically acceptable salts and “pharmaceutically acceptable salts” and “pharmaceutically acceptable salts” are interchangeable and include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salts” refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects.
- Inorganic acid salts include hydrochloride, hydrobromide, etc.; organic acid salts include formate, acetate, etc.
- the compound molecule of the present invention contains at least one nitrogen atom that can form a salt, it can be converted into the corresponding salt by reacting with the corresponding organic acid or inorganic acid in an organic solvent such as acetonitrile and tetrahydrofuran.
- organic acids include formic acid and acetic acid
- typical inorganic acids include hydrochloric acid and hydrobromic acid.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one of the above compounds and optionally one or more pharmaceutically acceptable carriers and/or diluents.
- compositions provided by the present invention can be prepared in any form, such as granules, powders, tablets, coated tablets, capsules, pills, syrups, drops, solutions, suspensions and emulsions, or as sustained release of active ingredients.
- Formulations, where examples of capsules include hard or soft gelatin capsules, granules and powders may be in non-effervescent or effervescent forms.
- compositions of the present invention may further include one or more pharmaceutically or physiologically acceptable carriers, which will be suitably formulated to facilitate administration.
- a pharmaceutically or physiologically acceptable carrier may be saline, hot pressurized water, Ringer's solution, buffered saline, glucose, alcohol, honey, mannitol, sorbitol, dextrin, lactose, caramel, gelatin, calcium sulfate , Magnesium stearate, talc, kaolin, glycerin, Tween, agar, calcium carbonate, calcium bicarbonate, surfactants, cyclodextrin and its derivatives, phospholipids, phosphates, starch and its derivatives, One or more of silicon derivatives, cellulose and its derivatives, pyrrolidones, polyethylene glycols, acrylic resins, phthalate esters, acrylic copolymers, and trimellitic acid esters.
- the pharmaceutical composition of the present invention may also include pharmaceutically or physiologically acceptable additives, such as diluents, lubricants, binders, glidants, disintegrants, sweeteners, flavoring agents, wetting agents, and dispersants. , surfactants, solvents, coating agents, foaming agents, or fragrances.
- diluents that may be used include, but are not limited to, lactose, sucrose, starch, salt, mannitol, and dicalcium phosphate;
- examples of lubricants include, but are not limited to, talc, starch, stearates of magnesium or calcium, lycopods, and Stearic acid;
- examples of binders include, but are not limited to, microcrystalline cellulose, tragacanth, glucose solution, arabic mucilage, gelatin solution, sucrose, and starch paste;
- examples of glidants include, but are not limited to, colloidal silica ;
- examples of disintegrants include, but are not limited to, croscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar, and carboxymethylcellulose;Sweetness
- flavoring agents include, but are not limited to, sucrose, lactose, mannitol
- Natural flavoring agents such as fruits, and better-tasting compounds, such as, but not limited to, peppermint and methyl salicylate;
- examples of humectants include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, Diethylene glycol monolaurate and polyoxyethylene lauryl ether.
- compositions of the present invention can be administered by various routes including oral, intravenous, intraarterial, intraperitoneal, intrathoracic, transdermal, nasal, inhalation, rectal, ocular and subcutaneous administration according to conventional methods.
- the compounds or pharmaceutical compositions provided by the present invention can treat inflammatory diseases or autoimmune diseases, such as psoriasis, inflammatory bowel disease or lupus erythematosus, through TYK2.
- inflammatory diseases or autoimmune diseases such as psoriasis, inflammatory bowel disease or lupus erythematosus, through TYK2.
- the general dosage range of the compounds provided by the present invention is about 0.05 mg/Kg to 1000 mg/kg per day, preferably about 1 mg/kg to 100 mg/kg, and more preferably about 1 to 50 mg/kg.
- the dosage range of the pharmaceutical composition is Calculated based on the amount of the above compounds it contains.
- compound 2 can be obtained by replacing 1c with 5-bromo-2-methyl-tetrazole.
- compound 3 can be obtained by replacing 1c with 3-bromo-1-cyclopropyl-1,2,4-triazole.
- the first step is the synthesis of 4-(5-methyl-2H-tetrazol-2-yl)-2-(trifluoromethoxy)aniline (4b)
- compound 5 can be obtained by replacing 1c with 1-methyl-5-bromotetrazole.
- compound 6 can be obtained by replacing 1c with 3-bromo-2-trifluoromethyl-1,2,4-triazole.
- compound 7 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 8 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 9 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 10 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 11 was obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 12 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 13 can be obtained by replacing 1c with 5-bromo-2-ethyl-tetrazole.
- compound 14 can be obtained by replacing 2-methyl-tetrazole with 2-ethyl-tetrazole.
- compound 15 can be obtained by replacing 1-methyl-5-bromotetrazole with 1-ethyl-5-bromotetrazole.
- compound 16 can be obtained by replacing 5-methyltetrazole with 5-ethyltetrazole.
- compound 17 can be obtained by replacing 2-ethyl-5-bromo-tetrazole with 2-ethyl-5-bromo-tetrazole.
- compound 18 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 19 can be obtained by replacing 3-bromo-2-trifluoromethyl-1,2,4-triazole with 2-(trifluoromethyl)-5-bromotetrazole.
- the third step Synthesis of 2-isopropoxy-4-(1-isopropyl-1H-pyrazol-4-yl)aniline (20g)
- compound 21 can be obtained by replacing 1-isopropyl-4-bromo-1H-pyrazole with 1-ethyl-4-bromo-1H-pyrazole.
- compound 22 can be obtained by replacing isopropanol with 2,2,2-trifluoroethanol.
- compound 23 can be obtained by replacing 1-isopropyl-4-bromo-1H-pyrazole with 1-methyl-4-bromo-1H-pyrazole.
- compound 24 can be obtained by replacing 1-isopropyl-4-bromo-1H-pyrazole with 1-methyl-4-bromo-1H-1,2,4-triazole.
- compound 25 can be obtained by replacing 1-isopropyl-4-bromo-1H-pyrazole with 1-cyclopropyl-4-bromo-1H-1,2,4-triazole.
- compound 26 can be obtained by replacing 1-isopropyl-4-bromo-1H-pyrazole with 2-bromo-5-cyanopyridine.
- compound 27 can be obtained by replacing isopropanol with cyclopropanol.
- Step 2 Synthesis of compound 4-[3-(2,2-difluoroethoxy)-4-nitrophenyl]-1-(isopropyl)-1H pyrazole (28d)
- Step 4 Compound 6-chloro-4-((4-[1-(isopropyl)-1H-pyrazole)-2-(2,2-difluoroethoxy)phenyl]amine)-N -Synthesis of (methyl-d3)pyridazine-3-carboxamide (28f)
- compound 29 can be obtained by replacing 20b with 28b.
- compound 30 can be obtained by replacing isopropyl alcohol with 2,2-difluoroethanol.
- compound 31 can be obtained by replacing isopropyl alcohol with 2,2,2-trifluoroethanol.
- compound 32 can be obtained by replacing 1-methyl-3-bromo-1H-1,2,4-triazole with 1-difluoromethyl-4-bromo-1H-pyrazole.
- compound 33 can be obtained by replacing 1-methyl-3-bromo-1H-1,2,4-triazole with 1-cyclopropyl-4-bromo-1H-pyrazole.
- compound 34 can be obtained by replacing 1-methyl-4-bromo-1H-pyrazole with 1-methyl-3-bromo-1H-1,2,4-triazole.
- compound 35 can be obtained by replacing 1-methyl-3-bromo-1H-1,2,4-triazole with 1-trifluoromethyl-4-bromo-1H-pyrazole.
- compound 36 can be obtained by replacing 28c with 1-cyclopropyl-1H-pyrazole-4-boronic acid pinacol ester.
- compound 37 can be obtained by replacing 1-methyl-3-bromo-1H-1,2,4-triazole with 1-ethyl-4-bromo-1H-pyrazole.
- compound 38 can be obtained by replacing 28c with 1-ethyl-1H-pyrazole-4-boronic acid pinacol ester.
- compound 39 can be obtained by replacing propanecarboxamide with (1s,2s)-2-fluorocyclopropanecarboxamide.
- compound 40 can be obtained by replacing propanecarboxamide with (1s,2s)-2-fluorocyclopropanecarboxamide.
- compound 41 can be obtained by replacing propanecarboxamide with 2,2-difluorocyclopropanecarboxamide.
- compound 43 can be obtained by replacing cyclopropylcarboxamide with 2,2-difluorocyclopropane-1-carboxamide.
- 3-bromo-1-(oxetane-3-methyl)-1H-1,2,4-triazole replaces 3-bromo-1-cyclopropyl-1H- Compound 45 can be obtained from 1,2,4-triazole.
- compound 47 can be obtained by replacing 1a with 2-(difluoromethoxy)-4-bromophenylamine.
- compound 48 can be obtained by replacing 3-bromo-1-propyl[1.2.4]triazole with 3-bromo-1-methyl[1.2.4]triazole.
- compound 49 can be obtained by replacing propanecarboxamide with 3,3-difluorocyclobutanecarboxamide.
- compound 51 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 3-bromo-1-methoxymethyl[1.2.4]triazole.
- compound 53 can be obtained by replacing propanecarboxamide with 2,2-difluorocyclopropanecarboxamide.
- compound 54 can be obtained by replacing 2,2-difluorocyclopropanecarboxamide with cyclopropanecarboxamide.
- compound 55 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 3-bromo-1-isopropyl[1.2.4]triazole.
- compound 57 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 1-methyl-3-bromopyrazole.
- compound 58 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 1-isopropyl-4-bromopyrazole.
- compound 59 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 1-cyclopropyl-4-bromopyrazole.
- compound 62 can be obtained by replacing isopropanol with isobutanol.
- compound 63 can be obtained by replacing isopropoxy group with difluoromethoxy group.
- compound 64 can be obtained by replacing 5-ethyltetrazole with 5-methyltetrazole.
- compound 65 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 2-bromo-5-methyl-[1.3.4]oxadiazole.
- the compound can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 4-bromo-1-(2-methoxy-eth-1-yl)pyrazole. 67.
- compound 68 can be obtained by replacing isopropyl alcohol with trifluoromethanol.
- compound 69 can be obtained by replacing isopropoxy group with difluoromethoxy group.
- compound 71 can be obtained by replacing cyclopropyl with fluorocyclopropyl.
- compound 72 can be obtained by replacing 3-bromo-1-methyltriazole with 4-bromo-1-(3,3,3-trifluoropropyl)pyrazole.
- compound 73 can be obtained by replacing 3-bromo-1-methyltriazole with 4-bromo-1-cyanomethylpyrazole.
- compound 79 can be obtained by replacing cyclopropyl with fluorocyclopropyl.
- compound 80 can be obtained by replacing 3-bromo-1-methyl[1.2.4]triazole with 5-fluoro-2-bromopyrimidine.
- compound 83 can be obtained by replacing 5-methyltetrazole with 4-trifluoromethylpyrazole.
- compound 83 can be obtained by replacing 5-methyltetrazole with 4-cyanopyrazole.
- compound 84 can be obtained by replacing 1-ethyl-4-bromopyrazole with 1-(2,2,2-trifluoroethyl)ethyl-4-bromopyrazole.
- compound 85 can be obtained by replacing 4-bromo-1-ethyl-1H-pyrazole with 4-bromo-1-isopropyl-1H-pyrazole.
- compound 86 can be obtained from 4-bromo-1-isopropyl-1H-imidazole-5-methyltetrazole.
- compound 88 can be obtained by replacing 28c with 1-methyl-1H-pyrazole-4-boronic acid pinacol ester.
- compound 89 can be obtained by replacing 4-bromo-1-(difluoromethyl)-1H-pyrazole with 4-bromo-1-isopropyl-1H-pyrazole.
- compound 90 can be obtained by replacing 4-bromo-1-methyl-1H-pyrazole with 4-bromo-1-isopropyl-1H-pyrazole.
- compound 91 can be obtained by replacing 4-bromo-1-isopropylpyrazole with 3-bromo-1-methyl[1.2.4]triazole.
- compound 92 can be obtained by replacing 4-bromo-1-trifluoroethylpyrazole with 4-bromo-1-isopropylpyrazole.
- compound 93 can be obtained by replacing cyclopropanecarboxamide with 2,2-difluorocyclopropane-1-carboxamide.
- compound 94 can be obtained by replacing propanecarboxamide with 2,2-difluorocyclopropanecarboxamide.
- compound 95 can be obtained by replacing cyclopropanecarboxamide with (2S)-2-fluorocyclopropane-1-carboxamide.
- compound 96 can be obtained by replacing propanecarboxamide with (1s,2s)-2-fluorocyclopropanecarboxamide.
- compound 97 can be obtained by replacing cyclopropanamide with 1s,2s-2-fluorocyclopropane-1-carboxamide.
- compound 97 can be obtained by replacing cyclopropanamide with 1R,2s-2-fluorocyclopropane-1-carboxamide.
- compound 99 can be obtained by replacing cyclopropanamide with 1s,2s-2-fluorocyclopropane-1-carboxamide.
- compound 100 can be obtained by replacing 2,2-difluoroethanol with 2-fluoroethanol.
- compound 101 can be obtained by replacing isopropyl alcohol with ethanol.
- compound 102 can be obtained by replacing 4-bromo-1-ethylpyrazole with 4-bromo-1-methylpyrazole.
- compound 103 can be obtained by replacing isopropyl alcohol with methanol.
- compound 104 can be obtained by replacing 4-bromo-1-isopropylpyrazole with 4-bromo-1-cyclopropylpyrazole.
- compound 105 can be obtained by replacing 1-ethyl-4-bromopyrazole with 3-bromo-1-aminomethylcarbonylmethyl-1,2,4-triazole.
- compound 106 can be obtained by replacing 4-bromo-1-methoxypyrazole with 4-bromo-1-ethylpyrazole.
- the compounds of the present invention have obvious inhibitory activity against TYK2JH2 pseudokinase.
- liquid chromatography-tandem mass spectrometry (LS/MS/MS) method was used to determine the drug concentration in the plasma of rats at different times after oral administration and intravenous administration of Compound 1 and Compound 7, and to calculate related pharmacokinetic parameters. , to evaluate the pharmacokinetic properties of the compounds of the present invention in rats.
- Example Compound 1 Example Compound 7.
- Blood was collected through the orbit before administration and 5 minutes, 15 minutes, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after administration. Each time, 0.2 milliliters (mL) of blood was collected and placed on the antibiotic. Place in a condenser tube, mix well, and store in a -20°C refrigerator for later use.
- liquid chromatography-tandem mass spectrometry (LS/MS/MS) method was used to determine the content of compounds in rat whole blood.
- the pharmacokinetic parameters of the compounds of the present invention after administration are shown in Table 3 below. As shown in Table 3, the compounds of the present invention have good metabolic characteristics and bioavailability.
- mice Purchase 8-week-old female BALB/c mice with an average weight of 20g.
- the experiment started after the mice adapted for 3 days.
- the experiment was divided into five groups: normal control group, model group, example compound group and positive drug group (BMS-986165), with 5-8 mice in each group.
- the mice in the model group, the example compound group and the positive drug group were anesthetized with intraperitoneal injection of pentobarbital sodium (80 mg/kg). After hair removal on the back, 62.5 mg of 5% imiquimod cream was evenly applied, once a day, normal The control group applied an equal amount of Vaseline.
- the example compound group (10 mg/kg) was administered intragastrically at 10 mL/kg once a day; the normal control group was intragastrically administered an equal amount of pure water, and the model group was intragastrically administered an equal amount of vehicle for 7 consecutive days.
- the specific design is shown in Table 4.
- mice 37 female BALB/c mice, 8 weeks old. Mice were purchased from Beijing Vitong Lihua Experimental Animal Technology Co., Ltd., license number SCXK (Shanghai) 2017-0011, animal certificate number: 20170011003865.
- Example Compound 1 Example Compound 7.
- the specific dosage is carried out according to the dosage regimen.
- mice The skin lesions of the mice were observed every day, and digital photography was used. According to the psoriasis area and severity index (PASI) scoring standards of the mice, erythema, scales and infiltration were given to the skin lesions of the mice. Score the degree (0: none; 1: mild; 2: moderate; 3: severe; 4: extremely severe) and observe the changes in the skin lesions of the mice in each group.
- PASI psoriasis area and severity index
- mice Purchase 40 8-week-old C57BL/6 female mice with an average weight of 20g.
- the animal experiment started after the mice adapted for 7 days.
- Each mouse was injected with mouse-derived IL-23 subcutaneously in the right ear, once every one day, for a total of 7 times, with a cycle of 14 days.
- the control and medication groups were orally gavaged twice a day from the first day of modeling. The specific design is shown in Table 5.
- Example test substance 1 Example test substance 7
- the efficacy results were analyzed by measuring the skin thickness of the right ear. After the administration, the skin tissue of the right ear was taken for HE staining, and the final efficacy results were confirmed by pathological scoring.
- Example Compound 1 After administration for 14 days, Example Compound 1, Example Compound 7 and BMS-986165 can all reduce the skin thickness of the right ear of mice, and the final pathological results show that Example Compound 1, Example Compound 7 and BMS-986165 can all improve inflammation. Infiltration, comprehensive pharmacodynamic result analysis shows that Example Compound 1 and Example Compound 7 can achieve the efficacy of high-dose BMS-986165 at low doses. Statistics show that Example Compound 1 and Example Compound 7 have the same efficacy in mice. The medicinal effect is better than BMS-986165.
- Example compound 1 and example compound 7 groups can significantly reduce the DAI score of mice on the third day of administration, inhibit the weight loss and colon shortening caused by DSS, and significantly reduce the intestinal damage caused by DSS to mice.
- Pathological examination The compound group of Examples was found to be able to effectively inhibit inflammatory infiltration in the colon.
- Example Compound 1 Male MRL/lpr mice were selected as the experimental animals of the lupus erythematosus model. The mice were evaluated for lymph node enlargement and skin damage every week, as well as related indicators of urinary albumin and creatinine. The in vivo drug efficacy test found that Example Compound 1, Example Compound 7 can significantly reduce the concentration of autoantibodies (anti-ds DNA, anti-SLE) and urinary protein in Pristane-induced lupus mice, reduce glomerular swelling, and can effectively reduce inflammatory cell infiltration in pathological tissue examination.
- autoantibodies anti-ds DNA, anti-SLE
- the purpose of this experiment is to test the acute toxic effects of the example compounds on mice.
- ICR mice SPF grade, 6-8 weeks old, half male and half male, were purchased from Shanghai Sipur-Bikai Experimental Animal Co., Ltd., license number SCXK (Shanghai) 2018-0006, animal certificate number: 20180006010983.
- Example Compound 1 Example Compound 7.
- ICR mice were given different doses of compounds at a single time and were observed continuously for 14 days to record the animal's death, poisoning reaction, weight changes, diet, appearance, behavior, etc. At the end point, animals were dissected, organs were removed, and histopathological examination and related hematological examination were performed.
- Example Compound 1 and Example Compound 7 were both greater than 1000 milligrams per kilogram (mg/kg). Compared with the mice in the control group, no mice in the administration group showed any signs of toxicity within 14 days from the date of administration. The body weight and behavior were abnormal, and no obvious abnormalities were found in related hematology. Pathological examination showed no toxic effects of the relevant example compounds, indicating that Example Compound 1 and Example Compound 7 of the present invention are safe and can be safely tolerated by animals.
- the purpose of this experiment is to test the long-term toxic effects of the example compounds on mice.
- ICR mice SPF grade, 6-8 weeks old, half male and half male, were purchased from Shanghai Sipur-Bikai Experimental Animal Co., Ltd., license number SCXK (Shanghai) 2018-0006, animal certificate number: 20180006010983.
- Example Compound 1 Example Compound 7.
- ICR mice were given different doses of compounds and observed continuously for 14 days. Animal death, poisoning reactions, weight changes, diet, appearance, behavior, etc. were recorded. At the end point, animals were dissected, organs were removed, and histopathological examination and related hematological examination were performed.
- Example Compound 1 and Example Compound 7 were both greater than 500 milligrams per kilogram (mg/kg). Compared with the mice in the control group, the mice in the administration group had no toxicity within 14 days from the date of administration. Abnormalities in body weight and behavior were observed, and no obvious abnormalities were found in related hematology. Pathological examination showed no toxic effects of the relevant example compounds, indicating that Example Compound 1 and Example Compound 7 of the present invention are safe and can be safely tolerated by animals.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了式(Ⅱ)所示的哒嗪类化合物、其制备方法和用途。本发明还公开了本发明化合物或其药物组合物在制备用于预防和/或治疗TYK2介导的疾病的药物中的用途。
Description
本发明属于医药领域,涉及一种哒嗪类化合物、其制备方法和用途。
银屑病属于自身免疫系统疾病,是由免疫介导的慢性、复发性、炎症性皮肤病,其发病机制复杂,目前无法彻底治愈。银屑病的传统疗法主要包括水疗、光疗、中药、水杨酸类等外用治疗方法,以及糖皮质激素、免疫抑制剂和维A酸类药物。由于生物制剂(主要为TNF剂抑制剂和IL抑制剂)和PDE4小分子抑制剂近年来的疗效显著,现已成为银屑病的主要治疗用药。
酪氨酸激酶2(Tyrosine Kinase 2,TYK2)是一种非受体酪氨酸激酶,属于Janus激酶(JAK)家族,在银屑病发病机制上起到重要作用。现有研究认为,部分适应性免疫系统的过度激活是银屑病发病的核心,在银屑病的发病过程中,多种免疫细胞和细胞因子共同导致下游角质细胞增殖,增加血管生成、促进内皮黏附分子的表达,同时激活的免疫细胞浸润到病变皮肤,最终形成银屑病。细胞因子IL-23介导的TH17途径的激活被认为是最主要的途径,而IL-23信号主要通过TYK2-JAK2和STAT3通路在细胞内介导相关效应。新型酪氨酸激酶2(Tyrosine Kinase 2,TYK2)抑制剂可以阻断受体刺激的TYK2的激活,从而抑制TYK2引起的STAT1和STAT3的磷酸化,从而抑制银屑病的发病过程。
本发明提供一类哒嗪化合物、其可药用盐及其同位素衍生物,其制备方法、药物组合物和其在预防和治疗与TYK2信号通路有关疾病药物中的用途。
发明内容
本发明提供一种通式(Ⅱ)所示的化合物或其可药用盐或同位素衍生物,
其中R1为-C1-3氘代烷基;
R2为-C3-6环烷基,其中所述的-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤
素中的一个或多个取代基所取代;
R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;
R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;
Ra为-H、-CN、-CF3、-C1-3烷基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基或-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代。
在本发明的一些实施方式中,
R1为-CD3;
R2为取代或未被取代的环丙烷基;
R3为-OCF3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-OCH(CH3)2或
在本发明的一些实施方式中,
R4为
Ra为-H、-CN、-CHF2、甲基、乙基、三氟甲基、-CH(CH3)2或环丙烷基。
在本发明的一些实施方式中,R1为-C1-3氘代烷基;
R2为-C3-6环烷基,其中所述的-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代;
R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;
R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;
Ra为-H、-CN、-CF3、-C1-3烷基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基或-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代。
在本发明的一些实施方式中,
R1为-CD3;
R2为取代或未被取代的环丙烷基;
R3为-OCF3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-OCH(CH3)2或
在本发明的一些实施方式中,
R4为
Ra为-H、-CN、-CHF2、甲基、乙基、三氟甲基、-CH(CH3)2或环丙烷基。
在本发明的一些实施方式中,
R1为-C1-3氘代烷基;
R2为-C3-6环烷基;
R3为卤素取代的C1-3烷氧基;
R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;
Ra为-H、-C1-3烷基、-C1-3卤代烷基、-C3-6环烷基或4-6元杂环基。
在本发明的一些实施方式中,R1为-CD3;
R2为环丙烷基;
R3为-OCF3或-OCHF2。
在本发明的一些实施方式中,
R4为任选被Ra取代5元杂芳基,所述杂芳基包含1、2、3或4个氮杂原子。
在本发明的一些实施方式中,R4为
Ra为-H、甲基、乙基、三氟甲基或环丙烷基。
在本发明的一些实施方式中,R1为-C1-3氘代烷基;
R2为-C3-6环烷基;
R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;
R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;
Ra为-H、-CN、-CF3、-C1-3烷基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基或-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代。
在本发明的一些实施方式中,
R1为-CD3;
R2为环丙烷基;
R3为-OCF3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-OCH(CH3)2或
在本发明的一些实施方式中,
R4为
Ra为-H、-CN、-CHF2、甲基、乙基、三氟甲基、-CH(CH3)2或环丙烷基。
在本发明的一些实施方式中,本发明的化合物或其可药用盐或同位素衍生物,选自如下化合物或其可药用盐或同位素衍生物:
本发明还提供了通式II所示的化合物的制备方法,可以是方案一或方案二,
方案一:
方案二:
化合物IIa硼酸化后和R4X反应得到化合物IId,或化合物IIa和R4H直接反应得到化
合物IId;
化合物IId和化合物IIe反应得到化合物IIf;
化合物IIf和R2C(O)NH2反应得到化合物II;
其中X为Br或I,R1、R2、R3和R4如前所述。
本发明还提供一种药物组合物,包括治疗有效量的式II所示化合物以及一种或多种药学上可接受的载剂和/或稀释剂。
本发明还提供所述的式II所示化合物或者所述的药物组合物在制备用于预防和/或治疗TYK2介导的疾病的药物中的用途。
在本发明的一些实施方式中,所述TYK2介导的疾病包括炎性疾病或自身免疫性疾病。
在本发明的一些实施方式中,所述炎性疾病和自身免疫疾病为银屑病、炎症性肠病或红斑狼疮。
本发明还提供治疗TYK2介导的疾病的方法,包括给需要这种治疗的患者施用治疗有效量的式II所示化合物。
定义和说明
除非另外定义,否则本文中所用的全部技术与科学术语均具有如本发明所属领域的普通技术人员通常理解的相同含义。
除非另有说明,否则采用本领域技术范围内的常规方法,如质谱、NMR、和药理学方法。除非提出具体定义,否则本文在分析化学、有机合成化学以及药物和药物化学的有关描述中采用的术语是本领域已知的。可在化学合成、化学分析、药物制备、制剂和递送,以及对患者的治疗中使用标准技术。例如,可利用厂商对试剂盒的使用说明,或者按照本领域公知的方式或本发明的说明来实施反应和进行纯化。通常可根据本说明书中引用和讨论的多个概要性和较具体的文献中的描述,按照本领域熟知的常规方法实施上述技术和方法。
术语“被取代的”是指所指定原子或基团上的任一个或多个氢被指定基团的选择替代,条件为不超过所指定原子的正常价态。当取代基是氧代或酮基(即=O)时,则所述原子上的2个氢被替代。
取代基和/或变量的组合仅在这些组合产生稳定化合物或可用的合成的中间体时才允许。稳定化合物或稳定结构是指足够稳定以经受自反应混合物以有用的纯度分离出并随后配制成有效治疗药物的化合物。
在本发明中,“任选”或“任选地”表示随后描述的事件或状况可能发生也可能不发生,且该描述同时包括该事件或状况发生和不发生的情况。“任选被取代”是指具有0个、1个、2个或更多个取代基的基团。本领域技术人员应理解,对于含有一或多个取代基的任何基团而言,这些基团不会引入任何立体上不合实际、合成上不可行和/或固有地不稳定的取代或取代模式。例如,“任选地被取代的芳基”表示芳基被取代或未被取代,且该描述同时包括被取代的芳基与未被取代的芳基。
术语“含有”或“包括(包含)”可以是开放式、半封闭式和封闭式的。换言之,所述术语也包括“基本上由…构成”、或“由…构成”。
除非具体指明,否则本文中化合物在其范围内涵盖化合物、其可药用盐及其同位素衍生物,本发明化合物在其范围内还涵盖其立体异构体、多晶型物、溶剂合物和前药。
除非具体指明,否则本文中立体异构体在其范围内涵盖互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、及其混合物形式。
术语“同位素衍生物”指化合物中一个或多个原子被其同位素(具有相同原子序数但原子质量或质量数不同于在自然界中占优势的原子质量或质量数的原子)替代的衍生物。同位素的实例包括但不限于,氢的同位素(例如2H、3H)、碳的同位素(例如11C、13C及14C)、氟的同位素(例如18F)、氮的同位素(例如13N及15N)、氧的同位素(例如15O、17O及18O)。本发明化合物包括本发明化合物的同位素衍生物,例如,化合物2的同位素衍生物
术语“烷基”或”亚烷基”是指包括具有指定碳原子数的支链和直链饱和脂肪族烃基。例如,“C1-C10烷基”(或亚烷基)是指包括C1、C2、C3、C4、C5、C6、C7、C8、C9和C10烷基。另外,例如,“C1-C6烷基”表示具有1至6个碳原子的烷基。烷基可以是未被取代的或被取代的,从而使它的一或多个氢被另一化学基团替代。烷基的实例包括但不限于,甲基(Me)、乙基(Et)、丙基(例如,正丙基和异丙基)、丁基(例如,正丁基、异丁基、叔丁基)、戊基(例如,正戊基、异戊基、新戊基)、己基(例如,正己基、异己基)等。术语“C1-3烷基”是指包含1至3个碳原子的烷基,具体指甲基、乙基、正丙基及异丙基。
术语“氘代烷基”是指烷基中的一或多个氢被氘替代,C1-3氘代烷基指一或多个氢被氘替代的甲基、乙基、正丙基及异丙基,例如氘代甲基包括CD3,CHD2,CH2D。
术语“卤素(halo或halogen)”是指氯、溴、氟和碘。
术语“卤代烷基”是指具有一或多个卤素取代基的被取代的烷基。例如,“氟代甲基”包
括CF3、CHF2、CH2F。
术语“烷氧基”(alkyloxy)是指本文所定义的烷基和氧原子连接形成的取代基。C1-3烷氧基指包含1至3个碳原子的烷氧基,例如,甲氧基、乙氧基、丙氧基和异丙氧基。
术语“卤代烷氧基”和“卤素取代的烷氧基”具有相同含义,是指具有一或多个卤素取代基的烷氧基。例如,“氟代甲氧基”包括OCF3、OCHF2、OCH2F。
术语“环烷基”是指环化的烷基,包括单环、二环或多环体系,其中单环、二环或多环体系的环不包含芳香环。所述环烷基基团可以独立地未被取代或被一个或多个本发明所描述的取代基所取代。
C3-6环烷基是指包含3至6个碳原子的环烷基。例如,环丙基、环丁基、环戊基、环己基等。术语“杂环”或“杂环基”具有相同的含义,是指包含至少一个环杂原子(例如,氮原子、氧原子或硫原子)的任何环结构(饱和的、不饱和的或芳族的)。杂环包括“脂杂环”和“芳杂环”。
在本发明的一些实施例中,杂环基为4-6元杂环基,其实例包括但不限于,呋喃基、咪唑烷基、咪唑啉基、咪唑基、异喹啉基、噻唑基、异噻唑基、异恶唑基、亚甲二氧基苯基、吗啉基、恶唑烷基、恶唑基、恶二唑基、1,2,3-恶二唑基、1,2,4-恶二唑基、1,2,5-恶二唑基、1,3,4-恶二唑基、1,2,4-恶二唑5(4H)-酮基、哌嗪基、哌啶基、哌啶酮基、4-哌啶酮基、吡喃基、吡嗪基、吡唑烷基、吡唑啉基、吡唑基、哒嗪基、吡啶基、嘧啶基、吡咯烷基、吡咯啉基、2H-吡咯基、吡咯基、四氢呋喃基、四唑基、噻吩基、四氢噻吩、1,2,3-三唑基、1,2,4-三唑基、1,2,5-三唑基、1,3,4-三唑基、氧杂环丁烷、氮杂环丁烷。术语“脂杂环”或“脂杂环基”具有相同的含义,是指没有芳香特征的杂环化合物,例如,氧杂环丁烷、氮杂环丁烷、吡咯烷基、2H-吡咯基、四氢呋喃基。
术语“芳杂环”、“芳杂环基”、“杂芳环”或“杂芳环基”具有相同的含义,是指有芳香特征的杂环化合物,包括单杂环芳基和稠杂环芳基。所述杂原子独立地选自氮、氧和硫,氮原子可以被取代或不被取代,氮和硫杂原子可任选被氧化(即,N→O和S(O)p,其中p=1或2),芳杂环中硫和氧原子的总数不超过1。
在本发明的一些实施方式中,单杂环芳基可以是5-6元杂芳基可以包含1-4个杂原子,例如吡咯、呋喃、噻吩、噻唑、异噻唑、咪唑、三唑、四唑、吡唑、噁唑、异噁唑、吡啶、吡嗪、哒嗪和嘧啶等。
典型的5-6元杂芳基包括但不限于,2-或3-噻吩基;2-或3-呋喃基;2-或3-吡咯基;2-、4-或5-咪唑基;3-、4-或5-吡唑基;2-、4-或5-噻唑基;3-、4-或5-异噻唑基;2-、4-
或5-唑基;3-、4-或5-异唑基;3-或5-1,2,4-三唑基;4-或5-1,2,3-三唑基;四唑基;2-、3-或4-吡啶基;3-或4-哒嗪基;3-、4-或5-吡嗪基;2-吡嗪基;2-、4-或5-嘧啶基。
在本发明的一些实施方式中,稠杂环芳基可以是三环、二环,例如苯并唑、苯并二唑、苯并噻唑、苯并咪唑、苯并噻吩、亚甲二氧基苯基、喹啉、异喹啉、萘啶、吲哚、苯并呋喃、嘌呤、苯并呋喃、脱氮嘌呤或中氮茚。
“杂芳基”的芳环可以在一个或多个环位置上被上文所述的取代基取代,例如卤素、羟基、烷氧基、烷基羰基氧基、芳基羰基氧基、烷氧基羰基氧基、芳基氧基羰基氧基、羟基羰基、烷基羰基、烷基氨基羰基、芳基烷基氨基羰基、烯基氨基羰基、烷基羰基、芳基羰基、芳基烷基羰基、烯基羰基、烷氧基羰基、氨基羰基、烷硫基羰基、磷酸酯、膦酸酯、氰基、氨基(包括烷基氨基、二烷基氨基、芳基氨基、二芳基氨基和烷基芳基氨基)、酰基氨基(包括烷基羰基氨基、芳基羰基氨基、氨基甲酰基和脲基)、脒基、亚氨基、巯基、烷硫基、芳硫基、羟基硫代羰基、硫酸酯、烷基亚磺酰基、磺酸酯基、氨磺酰基、磺酰氨基、硝基、三氟甲基、氰基、叠氮基、杂环基、烷基芳基,或芳族基团或杂芳族基团,其中芳基基团也可以与非芳族的脂环或杂环稠合或桥连,以形成多环(例如四氢萘)。
术语“药用盐”和“药用可接受的盐”、“药学上可接受的盐”可互换,其包括药学上可接受的酸加成盐和药学上可接受的碱加成盐。
“药学上可接受的酸加成盐”是指能够保留游离碱的生物有效性而无其它副作用的,与无机酸或有机酸所形成的盐。无机酸盐例如盐酸盐、氢溴酸盐等;有机酸盐例如甲酸盐、乙酸盐等。
在本发明的化合物分子中包含至少一个可成盐的氮原子时,可以通过在有机溶剂如乙腈、四氢呋喃中与相应的有机酸或无机酸反应,从而转化为相应的盐。典型的有机酸有甲酸、乙酸,典型的无机酸有盐酸、氢溴酸。
本发明还提供了一种药物组合物,其包含上述至少一个化合物以及任选一种或多种药学上可接受的载剂和/或稀释剂。
本发明所提供的药物组合物可以制备为任何形式,例如颗粒、粉末、片剂、包衣片剂、胶囊、药丸、糖浆、滴剂、溶液、混悬剂和乳剂,或者活性成分的缓释制剂,其中胶囊剂的实例包括硬或软明胶胶囊剂,颗粒剂和粉剂可以是非泡腾或泡腾形式。
本发明的药物组合物可进一步包括一种或多种医药或生理上可接受的载体,这些载体将适当配制以便于给药。例如,医药或生理上可接受的载体可以是盐水、热压水、林格氏液、缓冲盐水、葡萄糖、醇、蜂蜜、甘露醇、山梨醇、糊精、乳糖、焦糖、明胶、硫酸钙、
硬脂酸镁、滑石粉、高岭土、甘油、吐温、琼脂、碳酸钙、碳酸氢钙、表面活性剂、环糊精及其衍生物、磷脂类、磷酸盐类、淀粉类及其衍生物、硅衍生物、纤维素类及其衍生物、吡咯烷酮类、聚乙二醇类、丙烯酸树脂类、酞酸酯类、丙烯酸共聚物、苯三酸酯类中的一种或几种。
本发明的药物组合物还可以包括医药或生理上可接受的添加剂,例如稀释剂、润滑剂、粘合剂、助流剂、崩解剂、甜味剂、矫味剂、湿润剂、分散剂、表面活性剂、溶剂、涂层剂、发泡剂、或芳香剂。
可以使用的稀释剂的实例包括但不限于乳糖、蔗糖、淀粉、盐、甘露糖醇和磷酸二钙;润滑剂的实例包括但不限于滑石、淀粉、镁或钙的硬脂酸盐、石松子和硬脂酸;粘合剂的实例包括但不限于微晶纤维素、黄蓍胶、葡萄糖溶液、阿拉伯胶浆、明胶溶液、蔗糖和淀粉糊;助流剂的实例包括但不限于胶体二氧化硅;崩解剂的实例包括但不限于交联羧甲基纤维素钠、淀粉羟乙酸钠、藻酸、玉米淀粉、马铃薯淀粉、膨润土、甲基纤维素、琼脂和羧甲基纤维素;甜味剂的实例包括但不限于蔗糖、乳糖、甘露糖醇和人工甜味剂,例如环磺酸钠和糖精,和任意数量的喷雾干燥矫味剂;矫味剂的实例包括但不限于从植物提取的天然矫味剂,例如果实,和味道较好的化合物,例如但不限于薄荷和水杨酸甲酯;湿润剂的实例包括但不限于丙二醇一硬脂酸酯、脱水山梨醇一油酸酯、二甘醇一月桂酸酯和聚氧乙烯月桂基醚。
本发明的药物组合物可以根据传统方法来通过各种途径给药,包括口服、静脉内、动脉内、腹腔内、胸腔内、透皮、鼻腔、吸入、直肠、眼部和皮下导入。
经药理实验验证,本发明所提供的化合物或者药物组合物可通过TYK2治疗炎性疾病或自身免疫性疾病,所述炎性疾病和自身免疫疾病例如银屑病、炎症性肠病或红斑狼疮。
本发明所提供的化合物一般的剂量范围为约每天0.05mg/Kg至1000mg/kg,优选为约1mg/kg至100mg/kg,更优选为约1至50mg/kg,药物组合物的剂量范围为以其含有的上述化合物的量来计算。
通过以下实施例进一步举例描述本发明,这些方案是说明性的,并不以任何方式限制本发明。对本发明所作的本领域普通技术人员容易实现的任何改动或改变都将落入本发明的范围内。
化合物的制备方法
实施例1
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(1)的合成
第一步 4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-2-(三氟甲氧基)苯胺(1b)的合成
将4-溴-2-(三氟甲氧基)苯胺(5.00g,19.5mmol),双联硼(7.44g,29.3mmol),乙酸钾(4.78g,48.7mmol)和Pd(dppf)Cl2(1.42g,1.95mmol)混合于二氧六环(100mL)中,升温至110℃回流6小时。冷却过滤,滤液浓缩,通过硅胶柱层析纯化(0~20%EA/PE)得到目标产物4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-2-(三氟甲氧基)苯胺(4.2g,产率:71.0%)。
LCMS[M+H]+=304.2。
第二步 4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯胺(1d)的合成
将1b(4.2g,13.9mmol),1c(2.24g,13.9mmol)碳酸钾(4.80g,34.8mmol)和Pd(dppf)Cl2(1.01g,1.39mmol)混合于二氧六环(100mL)和水(12mL)中,升温至110℃,回流8小时。冷却过滤,滤液加入乙酸乙酯并振荡分层,有机相干燥浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~12%MeOH/DCM)得到目标产物4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯胺(2.3g,产率:64.3%)。
LCMS[M+H]+=259.2
第三步 6-氯-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)
哒嗪-3-甲酰胺(1f)的合成
将1d(500mg,1.94mmol),1e(524mg,2.52mmol)溶于无水四氢呋喃(30mL)中,冷却至0℃,慢慢滴加LiHMDS(4.85mL,1M in THF,4.85mmol),0℃下搅拌1小时。用饱和氯化铵溶液(20mL)淬灭,然后乙酸乙酯萃取两次。有机相用无水硫酸钠干燥、浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~12%MeOH/DCM)得到目标产物6-氯-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(350mg,产率:41.8%)。
LCMS[M+H]+=431.2。
第四步6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(1)的合成
将1f(350mg,0.81mmol),环丙酰胺(208mg,2.44mmol),碳酸铯(790mg,2.43mmol),Pd2(dba)3(222mg,0.24mmol)和xantphos(280mg,0.48mmol)混合于无水二氧六环(4mL)中,氮气保护,升温至120℃搅拌16小时。冷却过滤,滤液浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~12%MeOH/DCM)两次得到目标产物6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(80mg,产率:20.6%)。
LCMS[M+H]+=480.2。
1HNMR(400MHz,DMSO-d6)δ11.41(s,1H),11.11(s,1H),9.20(s,1H),8.57(s,1H),8.13(s,1H),8.01(dd,J=8.4,1.9Hz,1H),7.98-7.95(m,1H),7.73(d,J=8.4Hz,1H),3.93(s,3H),2.11-2.00(m,1H),0.86-0.74(m,4H).
实施例2
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(2-甲基-四氮唑-5-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(2)的合成
参考实施例1的合成方法,以5-溴-2-甲基-四氮唑替代1c可得化合物2。
LCMS[M+H]+=481.2。
1H NMR(400MHz,DMSO-d6)δ11.42(s,1H),11.27(s,1H),9.20(s,1H),8.21(s,1H),8.10(dd,J=8.5,1.9Hz,1H),8.04(q,J=1.6Hz,1H),7.83(d,J=8.4Hz,1H),4.43(s,3H),2.15–1.98(m,1H),0.81(dd,J=6.1,3.5Hz,4H).
实施例3
6-(环丙烷甲酰胺基)-4-((4-(1-环丙基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)-N-(甲基-d3)-哒嗪-3-甲酰胺(3)的合成
参考实施例1的合成方法,以3-溴-1-环丙基-1,2,4-三氮唑替代1c可得化合物3。
LCMS[M+H]+=506.2。
实施例4
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-甲基-2H-四唑-2-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(4)的合成
第一步 4-(5-甲基-2H-四唑-2-基)-2-(三氟甲氧基)苯胺(4b)的合成
将1a(1.0g,3.90mmol),4a(656mg,7.80mmol),碳酸铯(3.17g,9.75mmol),Pd2(dba)3
(892mg,0.98mmol)和xantphos(1.13g,1.96mmol)混合于无水二氧六环(20mL)中,氮气保护,升温至120℃搅拌16小时。冷却过滤,滤液浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~10%MeOH/DCM)得到目标产物4b(315mg,产率:31.1%)。
LCMS[M+H]+=260.2。
第二步 6-氯-N-(甲基-d3)-4-((4-(5-甲基-2H-四唑-2-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(4c)的合成
将1e(330mg,1.58mmol),4b(315mg,1.22mmol)溶于无水四氢呋喃(30mL)中,冷却至0℃,慢慢滴加LiHMDS(3.95mL,1M in THF,3.95mmol),0℃下搅拌1小时。用饱和氯化铵溶液(20mL)淬灭,然后乙酸乙酯萃取两次。有机相用无水硫酸钠干燥、浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~12%MeOH/DCM)得到目标产物4c(234mg,产率:44.5%)。
[M+H]+=432.2。
第三步 6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-甲基-2H-四唑-2-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(4)的合成
将4c(234mg,0.54mmol),环丙酰胺(138mg,1.63mmol),碳酸铯(529mg,1.63mmol),Pd2(dba)3(146mg,0.16mmol)和xantphos(185mg,0.32mmol)混合于无水二氧六环(3mL)中,氮气保护,升温至120℃搅拌16小时。冷却过滤,滤液浓缩,通过硅胶柱层析纯化(0~100%EA/PE,0~15%MeOH/DCM),然后通过制备HPLC得到目标产物4(32mg,产率:12.3%)。
LCMS[M+H]+=481.2。
实施例5
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-四唑-5-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(5)的合成
参考实施例1的合成方法,以1-甲基-5-溴四氮唑替代1c可得化合物5。
LCMS[M+H]+=481.2。
1H NMR(400MHz,DMSO-d6)δ11.46(d,J=7.7Hz,2H),9.24(s,1H),8.30(s,1H),8.01(q,J=1.6Hz,1H),7.95(dd,J=8.5,2.0Hz,1H),7.89(d,J=8.5Hz,1H),4.19(s,3H),2.12–2.03(m,1H),0.83(t,J=6.0Hz,4H).
实施例6
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(三氟甲氧基)-4-(1-(三氟甲基)-1H-1,2,4-三唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(6)的合成
参考实施例1的合成方法,以3-溴-2-三氟甲基-1,2,4-三氮唑替代1c可得化合物6。
LCMS[M+H]+=534.2。
实施例7
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(7)的合成
参考实施例1的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物7。
LCMS[M+H]+=462.2。
1HNMR(400MHz,DMSO-d6)δ11.35(s,1H),10.9(s,1H),9.14(s,1H),8.56(s,1H),8.10(s,1H),7.86-7.89(m,2H),7.61(d,1H),7.33(t,1H),3.92(s,3H),1.97-2.06(m,1H),0.79-1.02(m,4H)。
实施例8
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-甲基-2H-四唑-2-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(8)的合成
参考实施例4的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物8。
LCMS[M+H]+=463.2。
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),11.05(s,1H),9.17(s,1H),8.15(s,1H),7.99(dq,J=5.0,2.4Hz,2H),7.81(d,J=9.4Hz,1H),7.43(t,J=72.9Hz,1H),2.58(s,3H),2.12–2.01(m,1H),0.91–0.71(m,4H).
实施例9
6-(环丙烷甲酰胺基)-4-((4-(1-环丙基-1H-1,2,4-三唑-3-基)-2-(二氟甲氧基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(9)的合成
参考实施例3的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物9。
LCMS[M+H]+=488.2。
实施例10
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(2-甲基-2H-四唑-5-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(10)的合成
参考实施例2的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物10。
LCMS[M+H]+=463.2。
1HNMR(400MHz,DMSO-d6)δ11.38(s,1H),11.05(s,1H),9.15(s,1H),8.18(s,1H),
8.00-7.93(m,2H),7.74(d,1H),7.39(t,1H),4.43(s,3H),2.10-2.00(m,1H),0.82-0.79(m,4H)。
实施例11
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-四唑-5-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(11)的合成
参考实施例5的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a得化合物11。
LCMS[M+H]+=463.2。
实施例12
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(二氟甲氧基)-4-(1-(三氟甲基)-1H-1,2,4-三唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(12)的合成
参考实施例6的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物12。
LCMS[M+H]+=516.2。
实施例13
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(2-乙基-四氮唑-5-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(13)的合成
参考实施例2的合成方法,以5-溴-2-乙基-四氮唑替代1c可得化合物13。
LCMS[M+H]+=495.2。
1H NMR(400MHz,DMSO-d6)δ11.44(s,1H),11.26(s,1H),9.21(s,1H),8.20(s,1H),8.10(dd,J=8.4,1.7Hz,1H),8.05(s,1H),7.83(d,J=8.5Hz,1H),4.76(q,J=7.3Hz,2H),2.10–2.02(m,1H),1.56(t,J=7.3Hz,3H),0.85–0.77(m,4H).
实施例14
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-乙基-2H-四唑-2-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(14)的合成
参考实施例4的合成方法,以2-乙基-四氮唑替代2-甲基-四氮唑可得化合物14。
LCMS[M+H]+=495.2。
实施例15
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-乙基-1H-四唑-5-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(15)的合成
参考实施例5的合成方法,以1-乙基-5-溴四氮唑替代1-甲基-5-溴四氮唑可得化合物15。
LCMS[M+H]+=495.2。
1H NMR(400MHz,DMSO-d6)δ11.48(s,1H),11.45(s,1H),9.25(s,1H),8.29(s,1H),7.96(s,1H),7.88(s,2H),4.51(q,J=7.2Hz,2H),2.11–2.05(m,1H),1.45(t,J=7.3Hz,3H),0.89–0.77(m,4H).
实施例16
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-乙基-2H-四唑-2-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(16)的合成
参考实施例8的合成方法,以5-乙基四氮唑替代5-甲基四氮唑可得化合物16。
LCMS[M+H]+=477.2。
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),11.05(s,1H),9.17(s,1H),8.15(s,1H),8.00(dq,J=5.4,2.3Hz,2H),7.81(d,J=9.4Hz,1H),7.43(t,J=72.8Hz,1H),2.97(q,J=7.6Hz,2H),2.15–1.89(m,1H),1.34(t,J=7.6Hz,3H),0.91–0.67(m,4H).
实施例17
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(2-乙基-2H-四唑-5-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(17)的合成
参考实施例10的合成方法,以2-乙基-5-溴-四氮唑替代2-甲基-5-溴-四氮唑可得化合物17。
LCMS[M+H]+=477.3。
1HNMR(400MHz,DMSO-d6)δ11.41(s,1H),11.07(s,1H),9.18(s,1H),8.21(s,1H),8.00-7.94(m,2H),7.77-7.54(m,1H),7.41(t,1H),4.82(q,2H),2.15-2.08(m,1H),1.59(t,3H),0.82-0.62(m,4H)。
实施例18
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-乙基-1H-四唑-5-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(18)的合成
参考实施例15的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物18。
LCMS[M+H]+=477.3。
1HNMR(400MHz,DMSO-d6)δ11.42(s,1H),11.22(s,1H),9.19(s,1H),8.26(s,1H),7.81-7.74(m,2H),7.54-7.18(t,2H),4.52(q,2H),2.10-2.06(m,1H),1.45(t,3H),0.84-0.80(m,4H).
实施例19
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(二氟甲氧基)-4-(2-(三氟甲基)-四氮唑-5-基)苯基)氨基)哒嗪-3-甲酰胺(19)的合成
参考实施例12的合成方法,以2-(三氟甲基)-5-溴四氮唑替代3-溴-2-三氟甲基-1,2,4-三氮唑可得化合物19。
LCMS[M+H]+=517.2
实施例20
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(20)的合成
第一步 2-异丙氧基-4-溴硝基苯(20b)的合成
取一个三口瓶,依次加入异丙醇(4.2g,70mmol),THF(180ml),冰水浴下,氮气置换,加入NaH(3.0g,75mmol),冰水浴下搅拌10min,滴加化合物20a(10.95g,50mmol)的THF(20ml)。反应液于常温反应过夜。反应液饱和NH4Cl,EA萃取。合并有机相,无水Na2SO4干燥,过滤,浓缩。残余物用SiO2柱层析(PE/EA=2%)得化合物20b(7.2g)。
LCMS[M+H]+=261.2。
第二步 2-异丙氧基-4-(1-异丙基-1H-吡唑-4-基)硝基苯(20f)的合成
取一个单口瓶,依次加入化合物20b(2.6g,10mmol),20c(3.04g,12mmol),Pd(dppf)Cl2(731mg,1mmol),KOAc(1.56g,20mmol),1,4-dioxane(100ml)。常温下N2置换3次,反应液于100℃反应2小时。冷却,上述母液中,加入20e(2.07g,11mmol),K2CO3(3.0g,20mmol),H2O(40mL)。常温下N2换三次,110℃反应2h。反应液加水,EA萃取。合并有机相,无水Na2SO4干燥,过滤,浓缩。残余物用SiO2柱层析(PE/(EA:EtOH=3:1)=2-30%)得化合物20f(2.6g),油状物。
LCMS[M+H]+=290.2
第三步 2-异丙氧基-4-(1-异丙基-1H-吡唑-4-基)苯胺(20g)的合成
取一个单口瓶,依次加入化合物20f(2.6g,8.99mmol),Fe(2.5g,45mmol),饱和氯化铵水溶液(5ml),EtOH(30mL)。反应液于80℃反应1小时。过滤,浓缩。残余物用SiO2(DCM/MeOH=2to 5%)纯化得化合物20g(2.2g)褐色油状物
LCMS[M+H]+=260.2。
第四步 N-(甲基-d3)-4-((2-异丙氧基-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-6-氯-哒嗪-3-甲酰胺(20h)的合成
取一个三口瓶,依次加入化合物20g(388mg,1.5mmol),1e(407mg,1.95mmol),THF(30mL),常温下N2置换三次,加入LiHDMS(4.5ml,4.5mmol)。反应液常温反应3h。加水,EA萃取,干燥,过滤,浓缩。残余物用SiO2柱层析(PE/(EA:EtOH=3:1)=5-10%)纯化得化合物20h(370mg)。
LCMS[M+H]+=432.3。
第五步 6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(20)的合成
取一个单口瓶,依次加入化合物20h(200mg,0.46mmol),环丙酰胺(79mg,0.92mmol),1,4-dioxane(5mL),Pd(OAc)2(10mg,0.046mmol),Xantphos(53mg,0.092mmol),Cs2CO3(373g,1.15mmol),常温下N2置换三次,反应液110℃反应3h。加DCM/MeOH=10:1,用NaSO4过滤,浓缩。残余物用SiO2(PE/(EA:EtOH=3:1)=5-40%to DCM/MeOH=2%)纯化得化合物20(68mg)
LCMS[M+H]+=481.3。
1H NMR(400MHz,DMSO-d6)δ11.22(s,1H),10.66(s,1H),9.02(s,1H),8.26(d,J=0.8Hz,1H),8.03(s,1H),7.89(d,J=0.8Hz,1H),7.37–7.28(m,2H),7.20(dd,J=8.1,1.8Hz,1H),4.75–4.66(m,1H),4.52–4.41(m,1H),2.11–2.01(m,1H),1.43(d,J=6.7Hz,6H),1.24(d,J=6.0Hz,6H),0.87–0.73(m,4H).
实施例21
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(21)的合成
参考实施例20的合成方法,以1-乙基-4-溴-1H-吡唑替代1-异丙基-4-溴-1H-吡唑可得化合物21。
LCMS[M+H]+=467.3。
1H NMR(400MHz,DMSO-d6)δ11.25(s,1H),10.68(s,1H),9.05(s,1H),8.25(s,1H),8.05(s,1H),7.92(s,1H),7.35–7.33(m,2H),7.22–7.19(m,1H),4.75–7.69(m,1H),4.17–4.12(m,2H),2.09–2.04(m,1H),1.41(t,J=8.0Hz,3H),1.26(d,J=4.0Hz,6H),0.84–0.78(m,4H).
实施例22
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺
参考实施例20的合成方法,以2,2,2-三氟乙醇替代异丙醇可得化合物22。
MS m/z(ESI):521.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.56(s,1H),9.03(s,1H),8.28(s,1H),7.93(s,1H),7.86(s,1H),7.48(d,J=1.6Hz,1H),7.35(d,J=8.2Hz,1H),7.31(dd,J=8.2,1.6Hz,1H),4.83(q,J=8.7Hz,2H),4.49(p,J=6.6Hz,1H),2.04(ddd,J=12.4,7.7,4.9Hz,1H),1.44(d,J=6.7Hz,6H),0.82–0.72(m,4H).
实施例23
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(23)的合成
参考实施例20的合成方法,以1-甲基-4-溴-1H-吡唑替代1-异丙基-4-溴-1H-吡唑可得化合物23。
LCMS:453.3(M+1)
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.66(s,1H),9.03(s,1H),8.17(s,1H),8.03(s,1H),7.89(d,J=0.8Hz,1H),7.36–7.25(m,2H),7.18(dd,J=8.2,1.9Hz,1H),4.69(hept,J=6.2Hz,1H),3.84(s,3H),2.05(qd,J=7.4,5.0Hz,1H),1.24(d,J=6.0Hz,6H),0.87–0.71(m,4H).
实施例24
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-甲基-1H-1,2,4-三氮唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(24)的合成
参考实施例20的合成方法,以1-甲基-4-溴-1H-1,2,4-三氮唑替代1-异丙基-4-溴-1H-吡唑可得化合物24。
LCMS:454.3(M+1)
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.80(s,1H),9.06(s,1H),8.50(s,1H),8.13(s,1H),7.64(d,J=1.7Hz,1H),7.58(dd,J=8.3,1.7Hz,1H),7.45(d,J=8.2Hz,1H),4.65(hept,J=6.1Hz,1H),3.91(s,3H),2.11–1.99(m,1H),1.28(d,J=6.0Hz,6H),0.87–0.73(m,4H).
实施例25
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-环丙基-1H-1,2,4-三氮唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(25)的合成
参考实施例20的合成方法,以1-环丙基-4-溴-1H-1,2,4-三氮唑替代1-异丙基-4-溴-1H-吡唑可得化合物25。
LCMS(ESI-MS)m/z:480.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),10.80(s,1H),9.06(s,1H),8.62(s,1H),
8.13(s,1H),7.64(d,J=1.7Hz,1H),7.58(dd,J=8.2,1.7Hz,1H),7.45(d,J=8.2Hz,1H),4.66(p,J=6.0Hz,1H),3.85–3.75(m,1H),2.10–2.00(m,1H),1.28(d,J=6.0Hz,6H),1.17–1.11(m,2H),1.07–1.00(m,2H),0.82–0.77(m,4H).
实施例26
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(5-氰基吡啶-2-基)苯基)氨基)哒嗪-3-甲酰胺(26)的合成
参考实施例20的合成方法,以2-溴-5-氰基吡啶替代1-异丙基-4-溴-1H-吡唑可得化合物26。
LCMS(ESI-MS)m/z:475.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),11.05(s,1H),9.16–8.99(m,2H),8.38–8.21(m,3H),7.93(d,J=1.9Hz,1H),7.83(dd,J=8.4,1.9Hz,1H),7.56(d,J=8.4Hz,1H),4.92–4.56(m,1H),2.07(ddd,J=7.4,4.2,1.9Hz,1H),1.31(d,J=6.0Hz,6H),0.91–0.72(m,4H).
实施例27
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-环丙氧基-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(27)的合成
参考实施例20的合成方法,以环丙醇替代异丙醇可得化合物27。
MS m/z(ESI):479.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.22(s,1H),10.50(s,1H),9.03(s,1H),8.25(d,J=0.8Hz,1H),7.90–7.86(m,2H),7.55(d,J=1.8Hz,1H),7.34–7.20(m,2H),4.49(m,1H),3.98
(tt,J=6.0,2.9Hz,1H),2.05(ddd,J=12.4,7.6,4.8Hz,1H),1.44(d,J=6.6Hz,6H),0.84–0.74(m,6H),0.65–0.58(m,2H).
实施例28
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(28)的合成
第一步 化合物4-溴-2-(2,2-二氟乙氧基)-1-硝基苯(28b)的合成
将化合物28a(9.0g,41.3mmol)溶于DMF(165mL)中,依次加入Cs2CO3(26.8g,82.6mmol)和1,1-二氟-2-碘代乙烷(9.5g,49.5mmol),反应液N2保护下于110℃反应7小时。LCMS显示部分原料剩余。反应倒入冰水(300mL)淬灭,析出固体,过滤,滤饼用水洗涤,收集固体干燥得化合物28b(7.2g,收率61.8%)。
LCMS(ESI-MS)m/z:282.0(M+H+).
第二步:化合物4-[3-(2,2-二氟乙氧基)-4-硝基苯基]-1-(异丙基)-1H吡唑(28d)的合成
将化合物28b(1.5g,5.3mmol)溶于1,4-dioxane/H2O(20ml/4ml)中,加入化合物28c(1.51g,6.4mmol),Pd(dppf)Cl2(387mg,0.53mmol)和Cs2CO3(5.2g,15.9mmol)。反应液于氮气保护下90℃反应4小时。LCMS检测原料反应完全,反应液降至室温,加水(100
mL),EA(80mL*2)萃取。合并有机相,饱和食盐水(50mL)洗涤,无水Na2SO4干燥,过滤,浓缩。残余物柱层析(EA/PE=0-35%)得化合物28d(1.4g,收率84.8%)。
LCMS(ESI-MS)m/z:312.2(M+H+).
第三步 化合物2-(2,2-二氟乙氧基)-4-[1-(异丙基)-1H-吡唑-4-基]苯胺(28e)的合成
将化合物28d(1.3g,4.2mmol)溶于THF(20mL)中,加入10%的Pd/C(500mg)。H2保护下室温反应过夜。LCMS显示反应完全。反应液用Celite过滤,THF(20mL)淋洗。滤液减压浓缩,得化合物28e(1.1g,收率98%),直接用于下一步反应。
LCMS(ESI-MS)m/z:282.2(M+H+).
第四步 化合物6-氯-4-((4-[1-(异丙基)-1H-吡唑)-2-(2,2-二氟乙氧基)苯基]胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(28f)的合成
将化合物28e(0.9g,3.2mmol)和化合物1e(0.67g,3.2mmol)溶于THF(15mL)中,室温下加入LiHMDS(9.6mL,9.6mmol)。室温反应30min。LCMS显示反应完全。反应液倒入冰水(80mL)中,析出固体,固体用水洗涤两次,固体收集,干燥得化合物28f(1.0g,收率69%)。
LCMS(ESI-MS)m/z:454.2(M+H+).
第五步 6-(环丙烷甲酰胺)-4-((4-[1-(异丙基)-1H-吡唑)-2-(2,2-二氟乙氧基)苯基]胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(28)的合成
将化合物28f(400mg,0.88mmol)、环丙酰胺(150mg,1.76mmol)、dppf(98mg,0.176mmol)、K3PO4(560mg,2.64mmol)和1,4-dioxane(10mL)加入反应瓶,抽空换氮后,再加入Pd2(dba)3(81mg,0.088mmol),再次抽空换氮后,放入90℃油浴,反应5小时。LCMS显示反应完全。,反应液降至室温,加水(80mL),EA(50mL*2)萃取。合并有机相,饱和食盐水(30mL)洗涤,无水Na2SO4干燥,过滤,浓缩。残余物用Prep-HPLC制备得化合物28(79mg,收率17.8%)。
LCMS(ESI-MS)m/z:503.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.58(s,1H),9.04(s,1H),8.30(s,1H),7.91(d,J=15.0Hz,2H),7.42(s,1H),7.37–7.22(m,2H),6.28(t,J=54.8Hz,1H),4.56–4.34(m,3H),2.05(s,1H),1.44(d,J=6.7Hz,6H),0.86–0.68(m,4H).
实施例29
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(5-氰基吡啶-2-基)苯基)氨基)哒嗪-3-甲酰胺(29)的合成
参考实施例26的合成方法,以28b替代20b可得化合物29。
LCMS(ESI-MS)m/z:497.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.33(s,1H),10.96(s,1H),9.10(s,1H),9.06(d,J=2.1Hz,1H),8.38(dd,J=8.4,2.2Hz,1H),8.29(d,J=8.4Hz,1H),8.16(s,1H),7.97(d,J=1.9Hz,1H),7.91(dd,J=8.4,1.9Hz,1H),7.57(d,J=8.4Hz,1H),6.35(t,J=3.6Hz,1H),4.47-4.59(m,2H),2.03-2.09(m,1H),0.78-0.84(m,4H).
实施例30
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-甲基-1H-1,2,4-三氮唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(30)的合成
参考实施例24的合成方法,以2,2-二氟乙醇替代异丙醇可得化合物30。
LCMS(ESI-MS)m/z:476.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),10.75(s,1H),9.08(s,1H),8.54(s,1H),8.03(s,1H),7.78–7.61(m,2H),7.49(d,J=8.2Hz,1H),6.78–5.90(m,1H),4.46(td,J=14.5,3.5Hz,2H),3.93(s,3H),2.14–1.90(m,1H),0.92–0.72(m,4H).
实施例31
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-甲基-1H-1,2,4-三氮唑-3-基)苯基)氨基)哒嗪-3-甲酰胺(31)的合成
参考实施例24的合成方法,以2,2,2-三氟乙醇替代异丙醇可得化合物31。
MS m/z(ESI):494.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.72(s,1H),9.06(s,1H),8.54(s,1H),7.99(s,1H),7.76(d,J=1.7Hz,1H),7.70(dd,J=8.2,1.7Hz,1H),7.50(d,J=8.3Hz,1H),4.89(q,J=8.7Hz,2H),3.92(s,3H),2.05(t,J=5.5Hz,1H),0.83–0.73(m,4H).
实施例32
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-二氟甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(32)的合成
参考实施例31的合成方法,以1-二氟甲基-4-溴-1H-吡唑替代1-甲基-3-溴-1H-1,2,4-三氮唑可得化合物32。
LCMS[M+H]=529.3
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.66(s,1H),9.05(s,1H),8.79(s,1H),8.35(s,1H),7.93(s,1H),7.85(t,J=26.4Hz,1H),7.63(d,J=1.6Hz,1H),7.48–7.40(m,2H),4.86(q,J=8.7Hz,2H),2.09–2.01(m,1H),0.84–0.74(m,4H).
实施例33
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-环丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(33)的合成
参考实施例31的合成方法,以1-环丙基-4-溴-1H-吡唑替代1-甲基-3-溴-1H-1,2,4-三氮唑可得化合物33。
LCMS(ESI-MS)m/z:519.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.57(s,1H),9.04(s,1H),8.29(s,1H),7.93(s,1H),7.87(s,1H),7.48(d,J=1.7Hz,1H),7.41–7.28(m,2H),4.83(q,J=8.8Hz,2H),3.73(tt,J=7.4,3.9Hz,1H),2.09–2.02(m,1H),1.05(q,J=3.8,3.0Hz,2H),0.99(dd,J=7.2,4.5Hz,2H),0.83–0.71(m,4H).
实施例34
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(34)的合成
参考实施例31的合成方法,以1-甲基-4-溴-1H-吡唑替1-甲基-3-溴-1H-1,2,4-三氮唑可得化合物34。
LCMS(ESI-MS)m/z:493.20(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.24(s,1H),10.57(s,1H),9.01(s,1H),8.19(s,1H),7.93(s,1H),7.87(s,1H),7.47(s,1H),7.35–7.28(m,2H),4.87–4.80(q,2H),3.86(s,3H),2.06–2.01(m,1H),0.80–0.76(m,4H).
实施例35
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-三氟甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(35)的合成
参考实施例31的合成方法,以1-三氟甲基-4-溴-1H-吡唑替代1-甲基-3-溴-1H-1,2,4-三氮唑可得化合物35。
LCMS(ESI-MS)m/z:547.2(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.70(s,1H),9.09–9.00(m,2H),8.54(s,1H),7.96(s,1H),7.66(d,J=1.7Hz,1H),7.53–7.44(m,2H),4.86(q,J=8.7Hz,2H),2.09–2.01(m,1H),0.84–0.71(m,4H).
实施例36
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-环丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(36)的合成
参考实施例28的合成方法,以1-环丙基-1H-吡唑-4-硼酸频哪醇酯替代28c可得化合物36。
LCMS(ESI-MS)m/z:501.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.25(s,1H),10.60(s,1H),9.06(s,1H),8.32(s,1H),7.95(s,1H),7.91(s,1H),7.44(d,J=1.7Hz,1H),7.38–7.27(m,2H),6.46-6.13(m,1H),4.5-4.36(m,2H),3.79-3.69(m,1H),2.11–2.02(m,1H),1.12-0.95(m,4H),0.87-0.73(m,4H).
实施例37
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2,2-三氟乙氧基)-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(37)的合成
参考实施例31的合成方法,以1-乙基-4-溴-1H-吡唑替代1-甲基-3-溴-1H-1,2,4-三氮唑可得化合物37。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.56(s,1H),9.04(s,1H),8.25(s,1H),7.94(s,1H),7.87(s,1H),7.48(d,J=1.7Hz,1H),7.38–7.27(m,2H),4.84(q,J=8.7Hz,2H),4.14(q,J=7.3Hz,2H),2.08–2.00(m,1H),1.40(t,J=7.3Hz,3H),0.89–0.70(m,4H)..
实施例38
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(38)的合成
参考实施例28的合成方法,以1-乙基-1H-吡唑-4-硼酸频哪醇酯替代28c可得化合物38。
LCMS(ESI-MS)m/z:489.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.58(s,1H),9.04(s,1H),8.25(s,1H),7.92(d,J=16.9Hz,2H),7.42(d,J=1.8Hz,1H),7.33(d,J=8.2Hz,1H),7.26(dd,J=8.2,1.8Hz,1H),6.28(t,J=3.8Hz,1H),4.42(td,J=14.2,3.8Hz,2H),4.13(q,J=7.3Hz,2H),2.05(ddd,J=10.0,7.6,4.9Hz,1H),1.40(t,J=7.3Hz,3H),0.83–0.73(m,4H).
实施例39
6-((1s,2s)-2-氟环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(39)的合成
参考实施例28的合成方法,以(1s,2s)-2-氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物39。
LCMS(ESI-MS)m/z:521.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.60(s,1H),9.06(s,1H),8.30(s,1H),7.94(s,1H),7.89(s,1H),7.43(d,J=1.7Hz,1H),7.34(d,J=8.2Hz,1H),7.29(dd,J=8.2,1.7Hz,1H),6.27(t,J=3.8Hz,1H),4.99–4.79(m,1H),4.45(dtd,J=18.1,14.3,13.8,5.3Hz,3H),2.24(p,J=6.7Hz,1H),1.63–1.52(m,1H),1.44(d,J=6.7Hz,6H),1.18-1.10(m,1H)
实施例40
6-((1s,2s)-2-氟环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-异丙氧基-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(40)的合成
参考实施例21的合成方法,以(1s,2s)-2-氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物40。
LCMS(ESI-MS)m/z:485.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.30(s,1H),10.69(s,1H),9.06(s,1H),8.25(s,1H),8.03(s,1H),7.92(s,1H),7.36–7.34(m,2H),7.23–7.21(m,1H),5.02–4.84(m,1H),4.75–4.69(m,1H),4.17–4.12(m,2H),2.29–2.25(m,1H),1.64–1.57(m,1H),1.43–1.39(t,3H),1.27–1.25(d,6H),1.19–1.14(m,1H).
实施例41
6-(2,2-二氟环丙烷-1-甲酰胺基)-N-(甲基-d3)-4-((4-(1-甲基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(41)的合成
参考实施例1的合成方法,以2,2-二氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物41。
LCMS(ESI-MS)m/z:516.2(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.59(s,1H),11.13(s,1H),9.22(s,1H),8.57(s,1H),8.06(s,1H),8.03(dd,J=8.5,1.8Hz,1H),8.00–7.97(m,1H),7.74(d,J=8.4Hz,1H),3.93(s,3H),3.03(q,J=11.4,10.6Hz,1H),2.02(t,J=9.4Hz,2H).
实施例42
6-(2,2-二氟丙烷-1-羧酰胺)-4-((2-(2-(二氟甲氧基))-4-(1-甲基-1H-1,2,4-三氮唑-3-基)苯基)-N-(甲基-D3)吡啶嗪-3-羧酰胺(42)的合成
参考实施例16的合成方法,以3-溴-1-甲基-1H-1,2,4-三唑替代1c,以2,2-二氟环丙烷-1-甲酰胺替代环丙酰胺可得化合物42
LCMS[M+H]+=498.20
1H NMR(400MHz,DMSO-d6)δ8.52(s,1H),8.01(s,1H),7.91-7.83(m,2H),7.63(d,J=8.3Hz,1H),7.45-7.08(m,1H),3.91(s,3H),3.06-2.95(m,1H),2.04-1.93(m,2H).
实施例43
6-(2,2-二氟环丙烷-1-甲酰胺)-4-(2-二氟甲基)氧基-4-(2-甲基-2H-四唑-5-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(43)的合成
参考实施例10的合成方法,以2,2-二氟环丙烷-1-甲酰胺替代环丙基甲酰胺可得化合物43。
MS m/z(ESI):499.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.58(s,1H),11.08(s,1H),9.20(s,1H),8.12(s,1H),8.00–7.92(m,2H),7.76(d,J=8.4Hz,1H),7.39(t,J=73.1Hz,1H),4.43(s,3H),3.10–2.98(m,2H),2.01(q,J=9.6Hz,3H).
实施例44
4-((4-(1-环丙基-1H-1,2,4-三唑-3-基)-2-(二氟甲氧基)苯基)氨基)-6-(2,2-二氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(44)的合成
参考实施例42的合成方法,以3-溴-1-环丙基-1H-1,2,4-三唑替代3-溴-1-甲基-1H-1,2,4-三唑可得化合物44。
LCMS(ESI-MS)m/z:524.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.54(s,1H),10.93(s,1H),9.17(s,1H),8.67(s,1H),8.03(s,1H),7.90-7.86(m,2H),7.63(d,J=8.4Hz,1H),7.51-7.14(t,J=73.2Hz,1H),3.84-3.72(m,1H),3.07-2.99(m,1H),2.02-1.96(m,2H),1.21–1.02(m,4H).
实施例45
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(氧杂环丁烷-3-基甲基)-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(45)的合成
参考实施例9的合成方法,3-溴-1-(氧杂环丁烷-3-甲基)-1H-1,2,4-三唑替代3-溴-1-环丙基-1H-1,2,4-三唑可得化合物45。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),10.75(s,1H),9.11(s,1H),8.32(s,1H),7.95(d,J=13.8Hz,2H),7.56(dq,J=3.6,1.9Hz,2H),7.49(d,J=8.8Hz,1H),7.24(s,1H),4.99(q,J=5.8Hz,0.5H),4.83(q,J=5.7,5.3Hz,0.5H),4.49(p,J=6.6Hz,1H),2.25(t,J=7.1Hz,1H),1.63–1.54(m,1H),1.44(d,J=6.7Hz,6H),1.19–1.11(m,1H).
实施例46
6-(环丙基辅助酰基)-4-((2-(二氟甲氧基)-4-(1-乙基-1H-1,2,4-三唑-3-基)苯基)氨基)-n-(甲基-D3)-3-羧酰胺合成
参考实施例7的合成方法,以3-溴-1-乙基-1H-1,2,4-三唑替代3-溴-1-甲基-1H-1,2,4-三唑,可得化合物46。
LCMS[M+H]+=476.20
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),10.90(s,1H),9.14(s,1H),8.60(s,1H),8.10(s,1H),7.93-7.82(m,2H),7.62(d,J=8.3Hz,1H),7.50-7.14(m,1H),4.25(q,J=7.3Hz,2H),2.08-1.96(m,1H),1.43(t,J=7.3Hz,3H),0.83-0.79(m,4H).
实施例47
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-甲基-1H-四唑-1-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(47)的合成
参考实施例4的合成方法,以2-(二氟甲氧基)-4-溴苯氨替代1a可得化合物47。
LCMS[M+H]+=463.3。
1H NMR(400MHz,DMSO-d6)δ11.43(s,1H),11.17(s,1H),9.20(s,1H),8.24(s,1H),7.83(d,J=8.6Hz,1H),7.76(d,J=2.3Hz,1H),7.67(dd,J=8.6,2.4Hz,1H),7.35(t,J=72.8Hz,1H),2.60(s,3H),2.09(td,J=7.6,3.8Hz,1H),0.92–0.76(m,4H).
实施例48
6-[(环丙基羰基)氨基]-4-[2-(二氟甲氧基)-4-(1-丙基-1H-1,2,4-三唑-3-基)苯胺基]-N-(三氘代甲基)-哒嗪-3-甲酰胺(48)的合成
参考实施例7的合成方法,以3-溴-1-丙基[1.2.4]三氮唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物48。
LCMS(ESI-MS)m/z:490.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),10.91(s,1H),9.14(s,1H),8.62(s,1H),8.11(s,1H),7.91–7.88(m,2H),7.64–7.63(m,1H),7.46–7.22(m,1H),4.21–4.18(m,2H),2.09–2.06(m,1H),1.87–1.84(m,2H),0.88–0.81(m,7H).
实施例49
6-(3,3-二氟环丁烷-1-甲酰胺基)-N-(甲基-d3)-4-((4-(1-环丙基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(49)的合成
参考实施例3的合成方法,以3,3-二氟环丁烷甲酰胺替代丙烷甲酰胺可得化合物49。
LCMS(ESI-MS)m/z:556.3(M+H+).
1H NMR(600MHz,Chloroform-d)δ13.29(s,1H),10.39(s,1H),9.67(s,1H),8.17(s,1H),7.45(dd,J=8.0,1.7Hz,1H),7.40(td,J=7.6,1.3Hz,1H),7.35(td,J=7.8,1.6Hz,1H),7.17(d,J=8.2Hz,1H),3.68(dd,J=7.5,3.9Hz,1H),3.26(t,J=8.4Hz,1H),3.02–2.81(m,4H),1.30(d,J=3.8Hz,2H),1.19(d,J=7.2Hz,2H).
实施例50
6-(环丙基辅助酰基)-4-((2-(2-(二氟甲氧基)-4-(1-甲基-1H-吡唑-4-基)苯基)苯基)氨基)-n-(甲基-D3)吡啶嗪-3-吡啶嗪-3-羧酰胺(50)的合成
参考实施例16的合成方法,以1-甲基-4-溴吡唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物50
LCMS[M+H]+=461.30
1H NMR(400MHz,DMSO-d6)δ11.32(s,1H),10.80(s,1H),9.11(s,1H),8.04(s,1H),
7.75(d,J=2.2Hz,1H),7.70(d,J=8.6Hz,2H),7.53(d,J=8.2Hz,1H),7.46-7.10(m,1H),7.28(s,1H),6.76(d,J=2.3Hz,1H),3.88(s,3H),2.08-1.09(m,1H),0.81-0.77(m,4H).
实施例51
6-(2,2-二氟环丙烷-1-羧酰氨基)-4-((2-(二氟甲氧基)-4-(1-(甲氧基甲基)-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(51)的合成
参考实施例42的合成方法,以3-溴-1-甲氧基甲基[1.2.4]三氮唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物51。
LCMS(ESI-MS)m/z:528.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.57(s,1H),10.96(s,1H),9.19(s,1H),8.83(s,1H),8.06(s,1H),7.93(dd,J=8.3,1.8Hz,1H),7.90(d,J=1.7Hz,1H),7.67(d,J=8.3Hz,1H),7.35(t,J=73.2Hz,1H),5.53(s,2H),3.30(s,3H),3.08–2.98(m,1H),2.06–1.95(m,2H).
实施例52
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(2-(甲基氨基)乙基)-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(52)的合成
参考实施例7的合成方法,以3-溴-1-(2-氨甲基乙-2-基)-[1.2.4]三氮唑替代3-溴-1-
甲基[1.2.4]三氮唑可得化合物52。
LCMS(ESI-MS)m/z:505.3(M+H+).
1H NMR(400MHz,Methanol-d4)δ8.70(s,1H),8.17–8.12(m,2H),7.76(d,J=8.9Hz,1H),7.08(s,1H),7.05(t,J=7.2Hz,1H),4.74–4.67(m,2H),3.63(t,J=5.7Hz,2H),2.81(s,3H),1.92–1.85(m,1H),1.18–1.05(m,4H).
实施例53
4-((4-(1-环丙基-1H-1,2,4-三唑-3-基)-2-(三氟甲氧基)苯基)氨基)-6-(2,2-二氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(53)的合成
参考实施例3的合成方法,以2,2-二氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物53。
LCMS(ESI-MS)m/z:542.2(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.61(s,1H),11.65(s,1H),9.24(s,1H),8.71(s,1H),8.11-7.99(m,3H),7.76(d,J=5.6Hz,1H),3.87-3.83(m,1H),3.08–3.02(m,1H),2.05–2.00(m,2H),1.19–1.06(m,4H).
实施例54
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(甲氧基甲基)-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(54)的合成
参考实施例51的合成方法,以环丙烷甲酰胺替代2,2-二氟环丙烷甲酰胺可得化合物54。
LCMS(ESI-MS)m/z:491.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.30(s,1H),10.75(s,1H),9.10(s,1H),8.44(s,1H),8.07(d,J=0.80Hz,1H),7.99(s,1H),7.59-7.56(m,2H),7.51-7.49(m,1H),7.25(t,J=73.6Hz,1H),5.38(s,2H),3.25(s,3H),2.07–2.03(m,1H),0.81–0.77(m,4H).
实施例55
6-[(环丙基羰基)氨基]-4-{2-(二氟甲氧基)-4-[1-异丙基-1H-1,2,4-三唑-3-基]苯胺基}-N-(三氘代甲基)-哒嗪-3-甲酰胺(55)的合成
参考实施例7的合成方法,以3-溴-1-异丙基[1.2.4]三氮唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物55。
LCMS(ESI-MS)m/z:490.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.36(s,1H),10.91(s,1H),9.15(s,1H),8.65(s,1H),8.11(s,1H),7.92–7.87(m,2H),7.65–7.63(m,1H),7.52–7.15(m,1H),4.70–4.63(m,1H),2.09–2.06(m,1H),1.51–1.50(m,6H),0.85–0.81(m,4H).
实施例56
6-(环丙基辅助酰基)-4-((2-(2-(二氟甲氧基)-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)氨基)-n-(甲基-D3)吡啶嗪-3-吡啶嗪-3-羧酰胺的合成
参考实施例7的合成方法,以1-乙基-4-溴吡唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物56
LCMS[M+H]+=475.30
1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),10.72(s,1H),9.09(s,1H),8.27(d,J=0.8Hz,1H),7.99–7.90(m,2H),7.57–7.44(m,3H),7.42-7.05(m,1H),4.14(q,J=7.3Hz,2H),2.04-2.03(m,1H),1.39(t,J=7.3Hz,3H),0.85–0.74(m,4H).
实施例57
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-甲基-1H-吡唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(57)的合成
参考实施例7的合成方法,以1-甲基-3-溴吡唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物57。
LCMS(ESI-MS)m/z:461.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.31(s,1H),10.80(s,1H),9.11(s,1H),8.03(s,1H),7.75(d,J=2.2Hz,1H),7.71(d,J=1.9Hz,1H),7.68(d,J=1.8Hz,1H),7.53(d,J=8.1Hz,1H),6.76(d,J=2.3Hz,1H),3.88(s,3H),2.06(dt,J=6.1,3.7Hz,1H),0.85–0.66(m,4H).
实施例58
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(58)的合成
参考实施例7的合成方法,以1-异丙基-4-溴吡唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物58。
LCMS(ESI-MS)m/z:489.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),10.72(s,1H),9.09(s,1H),8.31(d,J=0.8Hz,1H),7.97(s,1H),7.92(d,J=0.8Hz,1H),7.56–7.51(m,2H),7.47(d,J=8.9Hz,1H),7.24(s,1H),4.49(p,J=6.6Hz,1H),2.04(td,J=7.6,3.9Hz,1H),1.43(d,J=6.7Hz,6H),0.86–0.73(m,4H).
实施例59
6-(环丙烷甲酰胺)-4-((4-(1-环丙基-1H-吡唑-4-基)-2-(二氟甲氧基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(59)的合成
参考实施例7的合成方法,以1-环丙基-4-溴吡唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物59。
LCMS(ESI-MS)m/z:487.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.30(s,1H),10.73(s,1H),9.09(s,1H),8.32(d,J=0.8Hz,1H),7.97(s,1H),7.92(d,J=0.8Hz,1H),7.56–7.51(m,2H),7.47(d,J=8.4Hz,1H),3.73(tt,J=7.4,3.9Hz,1H),2.10–2.01(m,1H),1.09–1.01(m,2H),1.01–0.93(m,2H),0.84–0.73(m,4H).
实施例60
6-[(环丙基羰基)氨基]-4-{2-(二氟甲氧基)-4-[1-(2-氨基-乙-1-基)-1H-1,2,4-三唑-3-基]苯胺基}-N-(三氘代甲基)-哒嗪-3-甲酰胺(60)的合成
参考实施例7的合成方法,以3-溴-1-(2-氨基-乙-1-基)[1.2.4]三氮唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物60。
MS m/z(ESI):491.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),10.89(s,1H),9.13(s,1H),8.57(s,1H),8.35(s,2H),8.08(s,1H),7.91–7.84(m,2H),7.62(d,J=8.3Hz,1H),7.32(t,J=73.2Hz,1H),4.20(s,2H),2.99(s,2H),2.10–2.01(m,1H),0.80(dd,J=6.4,3.2Hz,4H).
实施例61
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(2,2,2-三氟乙基)-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(61)的合成
参考实施例7的合成方法,3-溴-1-(2-氨基-乙-1-基)[1.2.4]三氮唑替代3-溴-1-甲基[1.2.4]三氮唑,可得化合物61。
LCMS(ESI-MS)m/z:530.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),11.16(s,1H),9.18(s,1H),8.24(s,1H),8.21(s,1H),7.78–7.71(m,1H),7.69–7.63(m,2H),7.36(t,J=7.2Hz,1H),5.31(q,J=8.8Hz,2H),2.12–2.02(m,1H),0.89–0.76(m,4H).
实施例62
6-((环丙基甲酰胺基)-4-((2-异丁氧基-4-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3))哒嗪-3-甲酰胺
参考实施例24的合成方法,以异丁醇替代异丙醇可得化合物62。
LCMS:468(M+1)
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.76(s,1H),9.06(s,1H),8.51(d,J=0.7Hz,1H),8.05(s,1H),7.64–7.55(m,2H),7.44(d,J=8.2Hz,1H),3.93–3.88(m,3H),3.85(d,J=6.3Hz,2H),2.10–1.91(m,2H),0.94(d,J=6.7Hz,6H),0.85–0.72(m,4H).
实施例63
4-((4-(1-(氰基甲基)-1H-1,2,4-三唑-3-基)-2-(二氟甲氧基)苯基)氨基)-6-(环丙烷甲酰胺)-N-(甲基-d3)哒嗪-3-甲酰胺(63)的合成
参考实施例7的合成方法,以二氟甲氧基替代异丙氧基可得化合物63。
LCMS(ESI-MS)m/z:487.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),8.55(s,1H),7.65(d,J=1.9Hz,1H),7.36(d,J=7.7Hz,1H),7.19(s,1H),7.10(s,2H),6.82(d,J=8.9Hz,1H),5.43(s,2H),2.05–1.96(m,1H),0.83–0.67(m,4H).
实施例64
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(5-乙基-1H-四唑-1-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(64)的合成
参考实施例8的合成方法,以5-乙基四氮唑替代5-甲基四氮唑可得化合物64。
LCMS[M+H]+=477.3。
1H NMR(400MHz,DMSO-d6)δ11.42(s,1H),11.15(s,1H),9.18(s,1H),8.22(s,1H),7.80(d,J=8.6Hz,1H),7.73(d,J=2.3Hz,1H),7.63(dd,J=8.6,2.3Hz,1H),7.32(t,J=72.8Hz,1H),2.90(q,J=7.5Hz,2H),2.14–1.99(m,1H),1.26(t,J=7.5Hz,3H),0.82(dd,J=6.6,4.4Hz,4H).
实施例65
6-(环丙烷甲酰胺基)-N-(三氘代甲基)-4-((4-(5-甲基-[1.3.4]恶二唑-2-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(65)的合成
参考实施例7的合成方法,以2-溴-5-甲基-[1.3.4]恶二唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物65。
MS m/z(ESI):463.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.41(s,1H),11.17(s,1H),9.17(s,1H),8.24(s,1H),7.91–7.82(m,2H),7.76(d,J=8.4Hz,1H),7.49(d,J=73.0Hz,1H),2.53(d,J=34.5Hz,3H),2.07(tt,J=7.3,5.1Hz,1H),0.81(t,J=2.3Hz,4H).
实施例66
6-(2,2-二氟环丙烷-1-甲酰胺)-4-((2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(66)的合成
参考实施例7的合成方法,可得化合物66。
LCMS(ESI-MS)m/z:525.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.51(s,1H),10.78(s,1H),9.15(s,1H),8.34(d,J=0.8Hz,1H),7.98–7.90(m,2H),7.59–7.48(m,3H),7.26(t,J=73.6Hz,1H),4.51(p,J=6.7Hz,1H),3.11–2.99(m,1H),2.06–1.95(m,2H),1.45(d,J=6.7Hz,6H).
实施例67
6-[(环丙基羰基)氨基]-4-{2-(二氟甲氧基)-4-[1-(2-甲氧基-乙-1-基)-1H-吡唑-4-基]苯胺基}-N-(三氘代甲基)-哒嗪-3-甲酰胺(67)的合成
参考实施例7的合成方法,以4-溴-1-(2-甲氧基-乙-1-基)吡唑替代3-溴-1-甲基[1.2.4]三氮唑可得化合物67。
MS m/z(ESI):505.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),10.73(s,1H),9.09(s,1H),8.23(s,1H),7.96(d,J=9.2Hz,2H),7.56–7.46(m,3H),7.25(t,J=73.6Hz,1H),4.26(t,J=5.2Hz,2H),3.70(t,J=5.3Hz,2H),3.23(s,3H),2.05(dd,J=8.5,4.0Hz,1H),0.83–0.75(m,4H).
实施例68
6-(环丙烷甲酰胺)-4-((4-(1-异丙基-1H-吡唑-4-基)-2-(三氟甲氧基)苯基)氨基)-N-(甲基
-d3)哒嗪-3-甲酰胺
参考实施例20的合成方法,以三氟甲醇替代异丙醇可得化合物68。
LCMS:507(M+1)
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),10.92(s,1H),9.15(s,1H),8.39(d,J=0.8Hz,1H),8.12–7.94(m,2H),7.79–7.64(m,2H),7.58(d,J=8.3Hz,1H),4.50(hept,J=6.6Hz,1H),2.07(tt,J=7.3,4.9Hz,1H),1.45(d,J=6.7Hz,6H),0.93–0.58(m,4H).
实施例69
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(丙-2-炔-1-基)-1H-1,2,4-三唑-5-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(69)的合成
参考实施例20的合成方法,以二氟甲氧基替代异丙氧基可得化合物69。
LCMS(ESI-MS)m/z:486.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),9.17(s,1H),8.40(s,1H),8.22(s,1H),8.09(s,1H),7.74(d,J=9.3Hz,3H),7.34(s,1H),5.23(d,J=2.6Hz,2H),3.56(s,1H),2.07(d,J=8.4Hz,1H),0.86–0.77(m,4H).
实施例70
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(1-(丙-2-炔-1-基)-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(70)的合成
参考实施例7的合成方法,4-溴-1-(3,3,3-三氟丙基)吡唑替代3-溴-1-甲基三氮唑,可得化合物70。
LCMS(ESI-MS)m/z:486.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),10.92(s,1H),9.13(s,1H),8.67(s,1H),8.11(s,1H),7.93–7.85(m,2H),7.64(d,J=8.3Hz,1H),5.21(d,J=2.6Hz,2H),3.58(t,J=2.5Hz,1H),2.05(q,J=6.1Hz,1H),0.80(d,J=6.1Hz,4H).
实施例71
-((2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-6-(2-氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(71)的合成
参考实施例58的合成方法,以氟代环丙基替代环丙基可得化合物71。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),10.74(s,1H),9.11(s,1H),8.32(d,J=0.8Hz,1H),7.96(s,1H),7.93(d,J=0.8Hz,1H),7.55(dq,J=3.5,1.9Hz,2H),7.49(d,J=8.8Hz,1H),5.00(dd,J=6.3,3.9Hz,1H),4.87–4.80(m,1H),4.49(p,J=6.7Hz,1H),2.25(p,J=6.8Hz,1H),1.64–1.51(m,1H),1.44(d,J=6.7Hz,6H),1.15(ddd,J=12.6,6.2,2.8Hz,1H).
实施例72
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-(3,3,3-三氟丙基)-1H-吡唑-4-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(72)的合成
参考实施例7的合成方法,以4-溴-1-(3,3,3-三氟丙基)吡唑替代3-溴-1-甲基三氮唑可得化合物72。
LCMS(ESI-MS)m/z:543.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.30(s,1H),10.74(s,1H),9.09(s,1H),8.34(s,1H),7.99(d,J=8.7Hz,2H),7.59–7.46(m,3H),7.25(t,J=73.5Hz,1H),4.39(t,J=6.8Hz,2H),2.90(tdd,J=11.2,6.9,4.4Hz,2H),2.05(tt,J=7.2,5.0Hz,1H),0.79(dq,J=7.5,3.3Hz,4H).。
实施例73
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(1-氰甲基-1H-吡唑-4-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(72)的合成
参考实施例7的合成方法,以4-溴-1-氰甲基吡唑替代3-溴-1-甲基三氮唑可得化合物73。
LCMS[M+H]+=486.3。
1H NMR(400MHz,DMSO-d6)δ11.31(s,1H),10.77(s,1H),9.10(s,1H),8.36(s,1H),8.12(s,1H),8.00(s,1H),7.60–7.48(m,3H),7.26(t,J=73.5Hz,1H),5.52(s,2H),2.00–1.90(m,1H),0.84–0.78(m,4H).
实施例74
4-((4-(5-氰基吡啶-2-基)-2-(二氟甲氧基)苯基)氨基)-6-(环丙烷甲酰胺)-N-
(甲基-d3)哒嗪-3-甲酰胺(74)的合成
参考实施例7的合成方法,2-溴-5-氰基吡啶替代3-溴-1-甲基三氮唑,可得化合物74。
LCMS(ESI-MS)m/z:483.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),11.14(s,1H),9.17(s,1H),9.09(dd,J=2.2,0.9Hz,1H),8.40(dd,J=8.4,2.2Hz,1H),8.28(dd,J=8.4,1.0Hz,1H),8.25(s,1H),8.18–8.11(m,2H),7.71(d,J=8.4Hz,1H),7.37(t,J=72Hz,1H),2.10-2.05(m,1H),0.81(h,J=3.1Hz,4H).
实施例75
4-((2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-6-((1R,2S)-2-氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(75)的合成
参考实施例66的合成方法,2-氟-环丙酰胺替代2,2-二氟-环丙酰胺,可得化合物75。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.44(s,1H),10.72(s,1H),9.12(s,1H),8.31(s,1H),7.92(s,1H),7.89(s,1H),7.54(s,1H),7.52–7.43(m,2H),7.23(t,J=72Hz,1H),4.94–4.89(m,0.5H),4.78–4.74(m,0.5H),4.49(p,J=6.6Hz,1H),2.64–2.53(m,1H),1.57–1.47(m,1H),1.43(d,J=6.7Hz,6H),1.21–1.13(m,1H).
实施例76
4-((2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)-6-((1S,2S)-2-氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(76)的合成
参考实施例75的合成方法,可得化合物76。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),10.75(s,1H),9.11(s,1H),8.32(s,1H),7.95(d,J=13.8Hz,2H),7.56(dq,J=3.6,1.9Hz,2H),7.49(d,J=8.8Hz,1H),7.06-7.43(s,1H),4.83-4.99(q,J=5.8Hz,1H),4.49(p,J=6.6Hz,1H),2.25(t,J=7.1Hz,1H),1.63–1.54(m,1H),1.44(d,J=6.7Hz,6H),1.19–1.11(m,1H).
实施例77
4-((2-(2-(二氟甲氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)苯基)氨基)-6-((1R,2R)-2-氟环丙烷-1-羧酰胺)-n-(甲基-D3)吡啶嗪-3-羧酰胺的合成
参考实施例75的合成方法,可得化合物77。
LCMS[M+H]+=507.30
1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),10.75(s,1H),9.11(s,1H),8.32(s,1H),7.96(s,1H),7.93(d,J=0.7Hz,1H),7.56-7.54(m,2H),7.49-7.47(m,1H),7.42-7.05(m,1H),5.00–4.80(m,1H),4.51-4.45(m,1H),2.26–2.22(m,1H),1.62–1.54(m,1H),1.43(d,J=6.7Hz,6H),1.17-1.12(m,1H).
实施例78
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(5-(甲基磺酰基)-5,6-二氢吡咯并[3,4-c]吡唑-2(4H)基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺
参考实施例8的合成方法,以5-(甲基磺酰基)-2,4,5,6-四氢吡咯并[3,4-c]吡唑替代5-甲基-2H-四唑可得化合物78。
LCMS:566(M+1)
1H NMR(400MHz,DMSO-d6)δ11.33(s,1H),10.79(s,1H),9.12(s,1H),8.44(s,1H),7.99(d,J=0.9Hz,1H),7.84–7.72(m,2H),7.63(d,J=8.7Hz,1H),7.32(d,J=1.0Hz,1H),4.50(d,J=12.8Hz,4H),3.03(d,J=0.9Hz,3H),2.05(td,J=7.5,3.8Hz,1H),0.87–0.72(m,4H).
实施例79
参考实施例58的合成方法,以氟代环丙基替代环丙基可得化合物79。
LCMS(ESI-MS)m/z:507.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),10.72(s,1H),9.12(s,1H),8.31(s,1H),7.91(d,J=13.3Hz,2H),7.56–7.50(m,2H),7.46(d,J=8.2Hz,1H),7.23(s,1H),4.92(s,1H),4.49(p,J=6.6Hz,1H),2.61(dt,J=20.2,8.9Hz,1H),1.52(ddd,J=18.6,6.5,3.3Hz,1H),1.43(d,J=6.7Hz,6H),1.20(dt,J=13.3,6.6Hz,1H).
实施例80
6-[(环丙基羰基)氨基]-4-({2-[(二氟甲基)氧基]-4-(5-氟嘧啶-2-基)苯基}氨基)-N-(三氘基甲基)-1,2-哒嗪-3-甲酰胺(80)的合成
参考实施例7的合成方法,以5-氟-2-溴嘧啶替代3-溴-1-甲基[1.2.4]三氮唑可得化合物80。
LCMS(ESI-MS)m/z:477.2(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),11.07(s,1H),9.16(s,1H),9.00(s,2H),8.40(s,1H),8.26–8.22(m,2H),7.73–7.71(m,1H),7.55–7.18(m,1H),2.10–2.04(m,1H),0.85–0.81(m,4H).
实施例81
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(4-三氟甲基-吡唑-1-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(81)的合成
参考实施例8的合成方法,以4-三氟甲基吡唑替代5-甲基四氮唑可得化合物83。
MS m/z(ESI):515.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.36(s,1H),10.88(s,1H),9.27(s,1H),9.14(s,1H),8.25(s,1H),8.04(s,1H),7.92–7.82(m,2H),7.70(d,J=8.8Hz,1H),7.33(t,J=73.0Hz,1H),2.06(ddd,J=12.5,7.5,4.7Hz,1H),0.86–0.69(m,4H).
实施例82
6-(环丙烷甲酰胺)-4-((2-(二氟甲氧基)-4-(5-(S-甲基磺酰亚胺基)-5,6-二氢吡咯并[3,4-c]吡唑-2(4H)-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺
参考实施例8的合成方法,以5-(S-甲基磺酰亚胺基)-2,4,5,6-四氢吡咯并[3,4-c]吡唑替代5-甲基-2H-四唑可得化合物82。
LCMS:565(M+1)
1H NMR(400MHz,DMSO-d6)δ11.33(s,1H),10.78(s,1H),9.12(s,1H),8.41(s,1H),7.98(s,1H),7.82–7.72(m,2H),7.62(d,J=8.7Hz,1H),7.32(s,1H),4.52–4.33(m,5H),2.95(s,3H),2.09–2.00(m,1H),0.88–0.72(m,4H).
实施例83
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((4-(4-氰基-吡唑-1-基)-2-(二氟甲氧基)苯基)氨基)哒嗪-3-甲酰胺(83)的合成
参考实施例8的合成方法,以4-氰基吡唑替代5-甲基四氮唑可得化合物83。
MS m/z(ESI):472.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.36(s,1H),10.91(s,1H),9.39(s,1H),9.14(s,1H),8.39(s,1H),8.05(s,1H),7.86(d,J=2.4Hz,1H),7.84–7.78(m,1H),7.72(d,J=8.8Hz,1H),7.55–7.10(t,J=332Hz,1H),2.10–2.02(m,1H),0.87–0.72(m,4H).
实施例84
6-[(环丙基羰基)氨基]-4-{2-(2,2-二氟乙氧基)-4-[1-(2,2,2-三氟乙基)-1H-吡唑-4-基]苯胺基}-N-(三氘基甲基)-哒嗪-3-甲酰胺(84)的合成
参考实施例38的合成方法,以1-(2,2,2-三氟乙基)乙基-4-溴吡唑替代1-乙基-4-溴吡唑可得化合物84。
LCMS(ESI-MS)m/z:543.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.25(s,1H),10.64(s,1H),9.07(s,1H),8.37(s,1H),8.14(s,1H),7.94(s,1H),7.49–7.48(m,1H),7.40–7.32(m,2H),6.45–6.16(m,1H),5.20–5.13(m,2H),4.50–4.42(m,2H),2.08–2.03(m,1H),0.82–0.78(m,4H).
实施例85
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-环丙氧基-4-(1-乙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(85)的合成
参考实施例27的合成方法,以4-溴-1-乙基-1H-吡唑替代4-溴-1-异丙基-1H-吡唑可得化合物85。
LCMS[M+H]+=465.3。
1H NMR(400MHz,DMSO-d6)δ11.22(s,1H),10.50(s,1H),9.04(s,1H),8.22(s,1H),7.97–7.77(m,2H),7.54(d,J=1.8Hz,1H),7.29(d,J=8.1Hz,1H),7.21(dd,J=8.1,1.8Hz,1H),4.14(q,J=7.3Hz,2H),3.97(tt,J=6.0,2.9Hz,1H),2.04(td,J=7.4,3.8Hz,1H),1.40(t,J=7.2Hz,3H),0.88–0.70(m,6H),0.62(dt,J=4.7,3.1Hz,2H).
实施例86
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-二氟甲氧基)-4-(1-异丙基-1H-咪唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(86)的合成
参考实施例8的合成方法,以4-溴-1-异丙基-1H-咪唑代5-甲基四氮唑可得化合物86
LCMS(ESI-MS)m/z:488.5(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),10.70(s,1H),9.09(s,1H),7.97(s,1H),7.87(d,J=1.4Hz,1H),7.76(d,J=1.3Hz,1H),7.71–7.63(m,2H),7.47(d,J=8.3Hz,1H),7.23(s,1H),4.43(p,J=6.7Hz,1H),2.04(h,J=5.9,5.1Hz,1H),1.43(d,J=6.7Hz,6H),0.79(dt,J=4.9,2.4Hz,4H).
实施例87
6-(环丙烷甲酰胺)-4-((2-(2,2-二氟乙氧基)-4-(1-(三氟甲基)-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺
参考实施例28的合成方法,以4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)-1-(三氟甲基)-1H-吡唑替代28c可得化合物87。
LCMS:529(M+1)
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.72(s,1H),9.06(d,J=9.9Hz,2H),8.55(s,1H),7.98(s,1H),7.61(d,J=1.6Hz,1H),7.50–7.36(m,2H),6.46–6.19(m,1H),4.45(td,J=14.1,3.9Hz,2H),2.05(td,J=7.7,4.0Hz,1H),0.89–0.68(m,4H).
实施例88
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(88)的合成
参考实施例28的合成方法,以1-甲基-1H-吡唑-4-硼酸频哪醇酯替代28c可得化合物88。
LCMS(ESI-MS)m/z:475(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.59(s,1H),9.04(s,1H),8.20(s,1H),7.92(d,J=14.9Hz,2H),7.41(d,J=1.8Hz,1H),7.33(d,J=8.2Hz,1H),7.25(dd,J=8.2,1.7Hz,1H),6.28(t,J=3.8Hz,1H),4.42(td,J=14.2,3.8Hz,2H),3.85(s,3H),2.05(tt,J=7.4,5.0Hz,1H),0.85–0.72(m,4H).
实施例89
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-环丙氧基-4-(1-二氟甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(89)的合成
参考实施例27的合成方法,以4-溴-1-(二氟甲基)-1H-吡唑替代4-溴-1-异丙基-1H-吡唑可得化合物89。
LCMS[M+H]+=487.3。
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.60(s,1H),9.05(s,1H),8.78(s,1H),8.32(s,1H),8.06–7.59(m,3H),7.36(s,2H),4.01(dt,J=6.0,3.1Hz,1H),2.14–1.95(m,1H),0.89–0.71(m,6H),0.69–0.57(m,2H).
实施例90
6-(环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-环丙氧基-4-(1-甲基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(90)的合成
参考实施例27的合成方法,以4-溴-1-甲基-1H-吡唑替代4-溴-1-异丙基-1H-吡唑可得化合物90。
LCMS[M+H]=451.3
1H NMR(400MHz,DMSO-d6)δ11.24(s,1H),10.52(s,1H),9.05(s,1H),8.53–8.39(m,1H),8.19(s,1H),7.90(d,J=6.6Hz,2H),7.55(s,1H),7.36–7.18(m,2H),4.04–3.93(m,1H),3.87(s,2H),2.17–1.90(m,2H),0.91–0.71(m,5H),0.70–0.54(m,2H).
实施例91
6-[(环丙基羰基)氨基]-4-{[2-(环丙基氧基)-4-(1-甲基-1,2,4-三氮唑-3-基)苯基]氨基}-N-(三氘基甲基)-1,2-哒嗪-3-甲酰胺(91)的合成
参考实施例27的合成方法,以3-溴-1-甲基[1.2.4]三氮唑替代4-溴-1-异丙基吡唑可得化合物91。
LCMS(ESI-MS)m/z:452.3(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.64(s,1H),9.06(s,1H),8.52(s,1H),8.01–7.92(m,2H),7.62(dd,J=8.2,1.8Hz,1H),7.42(d,J=8.2Hz,1H),3.98(dt,J=6.0,3.0Hz,1H),3.92(s,3H),2.05(p,J=6.6Hz,1H),0.86–0.74(m,5H),0.66(d,J=3.4Hz,2H).
实施例92
6-[(环丙基羰基)氨基]-N-(三氘基甲基)-4-({2-[(2,2,2-三氟乙基)氧基]-4-[1-(2,2,2-三氟乙基)吡唑-4-基]苯基}氨基)-哒嗪-3-甲酰胺(92)的合成
参考实施例22的合成方法,以4-溴-1-三氟乙基吡唑替代4-溴-1-异丙基吡唑可得化合物92。
LCMS[M+H]=560.9
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.63(s,1H),9.07(s,1H),8.36(s,1H),8.14(s,1H),7.91(s,1H),7.54(s,1H),7.44-7.33(m,2H),5.25-5.11(m,2H),4.94-4.82(m,2H),2.09–2.03(m,1H),0.90–0.68(m,4H).
实施例93
6-{[(2,2-二氟环丙基)羰基]氨基}-4-{[4-(1-乙基吡唑-4-基)-2-(丙-2-基氧基)苯基]氨基}-N-(三氘基甲基)-1,2-二氮杂环己熳-3-甲酰胺(93)的合成
参考实施例21的合成方法,以2,2-二氟环丙烷-1-甲酰胺替代环丙烷甲酰胺可得化合物93。
LCMS(ESI-MS)m/z:503.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.43(s,1H),10.69(s,1H),9.07(s,1H),8.24(s,1H),7.95-7.91(m,2H),7.33-7.20(m,3H),4.71(s,1H),4.12(s,2H),3.03(s,1H),1.99(s,2H),1.39(s,3H),1.24–1.21(m,6H).
实施例94
6-(2,2-二氟环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-异丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(94)的合成
参考实施例28的合成方法,以2,2-二氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物94。
LCMS(ESI-MS)m/z:539(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.23(s,1H),10.58(s,1H),9.04(s,1H),8.30(s,1H),7.91(d,J=15.0Hz,2H),7.42(s,1H),7.37–7.22(m,3H),6.28(t,J=54.8Hz,2H),4.51–4.37(m,3H),3.06–2.98(m,1H),2.01–1.94(m,2H),1.44(d,J=6.7Hz,6H).
实施例95
6-({[(2S)-2-氟环丙基]羰基}氨基)-4-{[4-(1-甲基吡唑-4-基)-2-[(2,2,2-三氟乙基)氧基]苯基]氨基}-N-(三氘基甲基)-1,2-二氮杂环己熳-3-甲酰胺(95)的合成
参考实施例34的合成方法,以(2S)-2-氟环丙烷-1-甲酰胺替代环丙烷甲酰胺可得化合物95。
LCMS(ESI-MS)m/z:511.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),10.59(s,1H),9.06(s,1H),8.20(s,1H),7.95(s,1H),7.86(s,1H),7.49(s,1H),7.38–7.36(m,1H),7.32–7.30(m,1H),5.01–4.97(m,1H)4.89–4.78(m,2H),3.86(s,3H),2.28–2.21(m,1H),1.60–1.52(m,1H),1.17–1.13(m,1H).
实施例96
6-({[(1R,2S)-2-氟环丙基]羰基}氨基)-4-[2-异丙氧基-4-(1-乙基-1H-吡唑-4-基)苯胺基]-N-(三氘基甲基)-哒嗪-3-甲酰胺(96)的合成
参考实施例21的合成方法,以(1s,2s)-2-氟环丙烷甲酰胺替代丙烷甲酰胺可得化合物96。
LCMS(ESI-MS)m/z:485.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.41(s,1H),10.69(s,1H),9.07(s,1H),8.25(s,1H),7.99(s,1H),7.92(s,1H),7.34–7.31(m,2H),7.21–7.18(m,1H),4.96–4.77(m,1H),4.74–4.68(m,1H),4.17–4.12(m,2H),2.66–2.58(m,1H),1.57–1.49(m,1H),1.43–1.39(m,3H),1.27–1.25(m,6H),1.23–1.18(m,1H).
实施例97
6-((1s,2s)-2-氟丙烷-1-羧酰胺)-4-(((2-异丙氧基-4-1-异丙基-1H-吡唑-4-苯基)苯基)-n-(甲基-d3)吡啶嗪-3-羧酰胺的合成
参考实施例20的合成方法,以1s,2s-2-氟环丙烷-1-甲酰胺替代环丙酰胺可得化合物97
LCMS[M+H]+=499.00
1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),10.68(s,1H),9.05(s,1H),8.27(d,J=0.8Hz,1H),8.02(s,1H),7.90(d,J=0.8Hz,1H),7.33(d,J=8.2Hz,2H),7.22(dd,J=8.2,1.8Hz,1H),5.01-4.81(m,1H),4.74-4.68(m,1H),4.50-4.44(m,1H),2.27-2.22(m,1H),1.63-1.54(m,1H),1.44(d,J=6.7Hz,6H),1.24(dd,J=6.0,3.6Hz,6H),1.18–1.09(m,1H).
\
实施例98
6-((1R,2s)-2-氟丙烷-1-羧酰胺)-4-(((2-异丙氧基-4-)(1-异丙基-1H-吡唑-4-苯基)苯基)-n-(甲基-d3)吡啶嗪-3-羧酰胺的合成
参考实施例20的合成方法,以1R,2s-2-氟环丙烷-1-甲酰胺替代环丙酰胺可得化合物97
LCMS[M+H]+=499.00
1H NMR(400MHz,DMSO-d6)δ11.39(s,1H),10.67(s,1H),9.06(s,1H),8.27(s,1H),7.97(s,1H),7.90(d,J=0.8Hz,1H),7.37–7.28(m,2H),7.19(dd,J=8.2,1.8Hz,1H),4.93-4.77(m,1H),4.75-4.58(m,1H),4.48(m,1H),2.66-2.55(m,1H),1.44(d,J=6.7Hz,6H),1.28–1.16(m,8H).
实施例99
4-((4-(1-环丙基-1H-吡唑-4-基)-2-(2,2,2-三氟乙氧基)苯基)氨基)-6-((1S,2S)-2-氟环丙烷-1-甲酰胺基)-N-(甲基-d3)哒嗪-3-甲酰胺(99)的合成
参考实施例33的合成方法,以1s,2s-2-氟环丙烷-1-甲酰胺替代环丙酰胺可得化合物99。
LCMS(ESI-MS)m/z:537.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),10.59(s,1H),9.06(s,1H),8.30(s,1H),7.94(s,1H),7.86(s,1H),7.49(d,J=1.7Hz,1H),7.41–7.29(m,2H),5.03–4.95(m,1H),4.92–4.75(m,2H),3.78–3.69(m,1H),2.29–2.19(m,1H),1.63–1.50(m,1H),1.18–1.11(m,1H),1.09–0.94(m,4H).
实施例100
6-(环丙烷甲酰胺)-4-((4-(1-乙基-1H-吡唑-4-基)-2-(2-氟乙氧基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(100)的合成
参考实施例38的合成方法,以2-氟乙醇替代2,2-二氟乙醇可得化合物100。
LCMS(ESI-MS)m/z:471.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.22(s,1H),10.63(s,1H),9.04(s,1H),8.24(d,J=0.9Hz,1H),7.96(s,1H),7.92(d,J=0.8Hz,1H),7.36(d,J=1.8Hz,1H),7.35–7.31(m,1H),7.23(dd,J=8.2,1.8Hz,1H),4.78–4.70(m,1H),4.66–4.59(m,1H),4.43–4.37(m,1H),4.35–4.29(m,1H),4.13(q,J=7.3Hz,2H),2.10–2.01(m,1H),1.40(t,J=7.3Hz,3H),0.84–0.72(m,4H).
实施例101
6-[(环丙基羰基)氨基]-4-[2-乙氧基-4-(1-乙基-1H-吡唑-4-基)苯胺基]-N-(三氘基甲基)-哒嗪-3-甲酰胺(101)的合成
参考实施例21的合成方法,以乙醇替代异丙醇可得化合物101。
LCMS(ESI-MS)m/z:453.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.24(s,1H),10.65(s,1H),9.05(s,1H),8.25(s,1H),8.00(s,1H),7.92(s,1H),7.33–7.31(m,2H),7.21–7.19(m,1H),4.18–4.12(m,4H),2.09–2.05(m,1H),1.43–1.39(m,3H),1.31–1.28(m,3H),0.83–0.78(m,4H).
实施例102
6-(环丙烷甲酰胺)-4-((2-乙氧基-4-(1-甲基-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺
参考实施例101的合成方法,以4-溴-1-甲基吡唑替代4-溴-1-乙基吡唑可得化合物102。
LCMS:439(M+1)
1H NMR(400MHz,DMSO-d6)δ11.24(s,1H),10.64(s,1H),9.05(s,1H),8.18(s,1H),7.98(s,1H),7.90(d,J=0.9Hz,1H),7.34–7.25(m,2H),7.17(dd,J=8.1,1.8Hz,1H),4.13(q,J=6.9Hz,2H),3.84(s,3H),2.05(td,J=7.4,3.8Hz,1H),1.28(t,J=6.9Hz,3H),0.79(dq,J=9.6,3.9,3.4Hz,4H).
实施例103
6-[(环丙基羰基)氨基]-N-(三氘基甲基)-4-({2-甲氧基-4-[1--乙基-吡唑-4-基]苯基}氨基)-哒嗪-3-甲酰胺(103)的合成
参考实施例21的合成方法,以甲醇替代异丙醇可得化合物103。
LCMS[M+H]=439.0
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.61(s,1H),9.08(s,1H),8.27(s,1H),7.97(d,J=19.1Hz,2H),7.40–7.27(m,2H),7.21(d,J=8.3Hz,1H),4.20-4.05(m,2H),3.87(s,3H),2.13-2.01(m,1H),1.50-1.30(m,3H),0.81(d,J=7.4Hz,4H).
实施例104
6-((1s,2s)-2-氟环丙烷甲酰胺基)-N-(甲基-d3)-4-((2-(2,2-二氟乙氧基)-4-(1-环丙基-1H-吡唑-4-基)苯基)氨基)哒嗪-3-甲酰胺(104)的合成
参考实施例39的合成方法,以4-溴-1-环丙基吡唑替代4-溴-1-异丙基吡唑可得化合物104。
LCMS[M+H]=519.0
1H NMR(400MHz,DMSO-d6)δ11.33(d,J=11.3Hz,1H),10.63(s,1H),9.09(s,1H),8.33(s,1H),7.93(d,J=19.6Hz,2H),7.43(d,J=14.7Hz,1H),7.40–7.22(m,2H),6.29(s,1H),5.00(s,1H),4.84(s,1H),4.54-4.32(m,2H),3.79–3.67(m,1H),2.31–2.20(m,1H),1.58(d,J=24.1Hz,1H),1.22–1.11(m,1H),1.11–0.90(m,4H).
实施例105
6-[(环丙基羰基)氨基]-4-{[2-(异丙基氧基)-4-(1-氨甲基羰基甲基-1,2,4-三氮唑-3-基)苯基]氨基}-N-(三氘基甲基)-1,2-哒嗪-3-甲酰胺(105)的合成
参考实施例21的合成方法,以3-溴-1-氨甲基羰基甲基-1,2,4-三氮唑替代1-乙基-4-溴吡唑可得化合物105。
MS m/z(ESI):511.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),10.82(s,1H),9.07(s,1H),8.53(d,J=1.0Hz,1H),8.23–8.15(m,1H),8.14(d,J=1.1Hz,1H),7.64(d,J=1.7Hz,1H),7.58(dd,J=8.2,1.7Hz,1H),7.46(d,J=8.3Hz,1H),4.91(s,2H),4.66(hept,J=6.0Hz,1H),2.63(d,J=4.6Hz,3H),2.05(p,J=6.2Hz,1H),1.28(dd,J=6.1,0.9Hz,6H),0.80(d,J=6.1Hz,3H).
实施例106
6-(环丙烷甲酰胺)-4-((2-乙氧基-4-(1-甲氧基-1H-吡唑-4-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺(106)的合成
参考实施例101的合成方法,以4-溴-1-甲氧基吡唑替代4-溴-1-乙基吡唑可得化合物106。
LCMS(ESI-MS)m/z:455.0(M+H+).
1H NMR(400MHz,DMSO-d6)δ11.26(s,1H),10.67(s,1H),9.06(s,1H),8.37(d,J=1.2Hz,1H),8.00(s,1H),7.80(d,J=1.2Hz,1H),7.35–7.30(m,2H),7.22(dd,J=8.2,1.7Hz,1H),4.14(q,J=6.9Hz,2H),4.08(s,3H),2.09–2.01(m,1H),1.28(t,J=6.9Hz,3H),0.84–0.73(m,4H).
生物活性试验
实验一、本发明TYK2抑制剂小分子化合物的体外活性测定
1.实验目的
本实验通过荧光共振能量转移(TR-FRET)法测试本发明化合物(化合物1-化合物40)对TYK2JH2假激酶的抑制作用,根据半抑制浓度(IC50)评价化合物的体外活性。
2.实验方法
2.1准备1×实验工作液
实验工作液配制
2.2实验流程
(1)用DMSO溶解化合物到10mM的存储浓度。
(2)在化合物稀释板子中配备200倍于终浓度的化合物浓度,按照27倍倍比稀释法,从最高浓度点稀释,共4个浓度点,并转移到Echo板中。
(3)用Echo仪器将化合物从Echo板脉冲到384实验板,使得化合物变成3倍倍比稀释矩阵,11个浓度点。
(4)加5ul 3X TYK2JH2激酶到384实验板中。
(5)加5ul 3X Tb到384实验板中。
(6)加5ul 3X Tracer到384孔实验板中。
(7)离心30秒,室温孵育60分钟。
(8)Envision酶标仪(PerkinElmer)495/520荧光信号值。
(9)使用XL-Fit软件进行数据分析,得出化合物IC50。
2.3实验结果
表1本发明化合物体外活性实验结果
结论:本发明化合物对TYK2JH2假激酶具有明显的抑制活性。
实验二、本发明化合物在大鼠中药物代谢动力学实验
1.实验目的:
以SD大鼠为例,以液相色谱-串联质谱(LS/MS/MS)法测定了大鼠分别灌胃和静脉给予化合物1、化合物7后不同时刻血浆中药物浓度并计算相关药代参数,评价本发明实施例化合物在大鼠体内的药代动力学特性。
2.试验方案
2.1试验药物
实施例化合物1、实施例化合物7。
2.2试验动物
健康成年的SD大鼠,SPF级,雄性,购自上海西普尔-必凯实验动物有限公司,许可证号SCXK(沪)2018-0006,动物合格证编号:20180006006321。
2.3药物配置
称取一定量的化合物,溶于5%乙醇(ethanol)涡旋超声,加入5%水溶性天然维生素E(TPGS,配置前需加热)混匀,加入90%纯水混匀配置成1mg/mL的均一口服溶液。称取一定量的化合物,溶于80%聚乙二醇400(PEG400)涡旋超声,再加入20%纯水配置成0.4mg/mL澄清透明静脉给药溶液。
2.4给药
具体给药按照试验方案进行,详情见表2。
表2大鼠药代动力学试验方案
2.5采血时间及样品处理
给药前及给药后5分钟、15分钟、0.5小时、1小时、2小时、4小时、6小时、8小时及24小时分别通过眼眶采血,每次采血0.2毫升(mL),置于抗凝管中,混匀,保存于-20℃冰箱中备用。
3.样品测试及数据分析
采用液相色谱-串联质谱(LS/MS/MS)方法测定大鼠全血中化合物的含量。
利用WinNonLin5.3软件的非房室模型计算给药后化合物的药代动力学参数。
4.试验结果
本发明化合物给药后药代动力学参数见以下表3。由表3所示,本发明的化合物具有较好的代谢特征及生物利用度。
表3本发明的化合物的药代动力学参数
实验三、本发明化合物的小鼠体内药效实验
一、银屑病模型
1.造模及给药
购买8周龄雌性BALB/c小鼠,平均体重20g。小鼠适应3天后开始实验,实验分为五组,正常对照组、模型组、实施例化合物组及阳性药组(BMS-986165),每组5-8只。模型组、实施例化合物组及阳性药组小鼠用戊巴比妥钠腹腔注射麻醉(80mg/kg),背部去毛后均匀涂抹5%咪喹莫特乳膏62.5mg,每日一次,正常对照组涂抹等量凡士林。实施例化合物组(10mg/kg)按10mL/kg灌胃给药,每日一次;正常对照组灌胃等量纯水,模型组灌胃等量溶媒,连续7d。具体设计见表4。
表4化合物体内药效实验方案
NA表示空白项。
NA表示空白项。
2.实验动物
雌性BALB/c小鼠37只,8周龄。小鼠均购自北京维通利华实验动物技术有限公司,许可证号SCXK(沪)2017-0011,动物合格证编号:20170011003865。
3.实验药物
实施例化合物1、实施例化合物7。
4.药物的配置
称取适量化合物,溶于5%乙醇(ethanol)涡旋超声,加入5%水溶性天然维生素E(TPGS,配置前需加热)混匀,加入90%纯水混匀配置成1mg/mL的均一溶液。
5.给药
具体给药按照给药方案进行。
6.检测指标和方法
每天观察小鼠皮损情况,并采用数码照相,依据小鼠银屑病样皮损面积和疾病严重程度(psoriasis area and severity index,PASI)评分标准,给予小鼠皮损处红斑、鳞屑及浸润程度(0:无;1:轻度;2:中度;3:重度;4:极重度)打分,观察各组小鼠皮损的变化情况。
7.实验结果及结论
咪喹莫特外涂与小鼠背部皮肤5d后,模型对照组小鼠背部皮损增厚、浸润显著,大量斑块状鳞屑出现,皮肤变红。实施例化合物1、实施例化合物7组小鼠皮损红斑和鳞屑明显减少,浸润减轻。模型对照组小鼠PASI评分随天数持续增高,实施例化合物1、实施例化合物7组第3天后PASI评分开始明显降低,作用效果优于阳性药组。
二、银屑病模型
1.造模及给药。
购买8周龄C57BL/6雌性小鼠40只,平均体重为20g。小鼠适应7天后开始动物实验,每只小鼠在右耳皮下注射鼠源IL-23,间隔一天注射一次,共7次,周期为14天。对照及给药组从造模第一天每天口服灌胃2次,具体设计见表5。
表5化合物体内药效实验方案
NA表示空白项
NA表示空白项
2.试验药物
实施例受试物1、实施例受试物7
1.药物配置
称取适量化合物,溶于5%乙醇(ethanol)涡旋超声,加入5%水溶性天然维生素E(TPGS,配置前需加热)混匀,加入90%纯水混匀配置成1.5mg/mL的均一溶液。
2.给药
具体给药以实验方案设计进行
3.检测指标和方法
通过右耳皮肤厚度测量进行药效结果分析,给药结束后取右耳皮肤组织进行HE染色,通过病理评分来确认最后药效结果。
4.实验结果及讨论
通过给药14天,实施例化合物1、实施例化合物7及BMS-986165均能减少小鼠右耳皮肤厚度,最终病理结果显示实施例化合物1、实施例化合物7及BMS-986165均能改善炎症浸润,综合药效结果分析显示实施例化合物1及实施例化合物7在低剂量下便能达到高剂量BMS-986165的药效,统计学显示实施例化合物1及实施例化合物7在小鼠体内的药效作用优于BMS-986165。
三、炎症性肠病模型
口服灌胃2.5%葡聚糖硫酸钠(DSS)诱导小鼠IBD造模后,模型组小鼠出现体重减轻、精神萎靡、嗜睡、血便、腹泻等症状,其疾病活动指数(DAI)明显高于对照组。实施例化合物1、实施例化合物7组在给药第三天能够显著降低小鼠的DAI评分,抑制DSS带来的体重下降和结肠缩短,显著减轻DSS对小鼠的肠道损伤,病理学检查发现实施例化合物组能够有效抑制结肠中的炎症浸润。
四、红斑狼疮模型
选择雌性MRL/lpr小鼠作为红斑狼疮模型的实验动物,每周评估小鼠淋巴结肿大及皮肤损伤,及相关尿白蛋白及肌酐的指标测试,体内药效试验发现实施例化合物1、实施例化合物7能显著降低Pristane诱导的狼疮小鼠自身抗体(anti-ds DNA,anti-SLE)和尿蛋白浓度,降低肾小球肿胀度,病理学组织检查中发现能够有效减少炎症细胞浸润。
实验四、本发明化合物的小鼠急毒实验
1.实验目的
本实验目的是为了测试实施例化合物在小鼠上的急性毒性作用。
2.实验动物
ICR小鼠,SPF级,6-8周龄,雌雄各半,购自上海西普尔-必凯实验动物有限公司,许可证号SCXK(沪)2018-0006,动物合格证编号:20180006010983。
3.试验药物
实施例化合物1、实施例化合物7。
4.实验方法
ICR小鼠单次给予不同剂量的化合物,连续观察14天,记录动物死亡情况,中毒反应,体重变化,饮食,外观,行为等。终点解剖动物,取脏器,进行组织病理学检查及相关血液学检查。
5.实验结果及结论
实施例化合物1、实施例化合物7的无毒性反应剂量(NOAEL)均大于1000毫克每公斤(mg/kg),与对照组小鼠比较,给药组小鼠自给药日起14天内均未见体重及行为异常,且相关血液学未见明显异常,病理学检查未见相关实施例化合物毒性作用,说明本发明实施例化合物1、实施例化合物7安全性良好,动物能够安全耐受。
实验五、本发明化合物的小鼠长毒实验
1.实验目的
本实验目的是为了测试实施例化合物在小鼠上的长期毒性作用。
2.实验动物
ICR小鼠,SPF级,6-8周龄,雌雄各半,购自上海西普尔-必凯实验动物有限公司,许可证号SCXK(沪)2018-0006,动物合格证编号:20180006010983。
3.试验药物
实施例化合物1、实施例化合物7。
4.实验方法
ICR小鼠给予不同剂量的化合物,连续给药观察14天,记录动物死亡情况,中毒反应,体重变化,饮食,外观,行为等。终点解剖动物,取脏器,进行组织病理学检查及相关血液学检查。
5.实验结果及结论
实施例化合物1、实施例化合物7的无毒性反应剂量(NOAEL)均大于500毫克每公斤(mg/kg),与对照组小鼠比较,给药组小鼠自给药日起,14天内均未见体重及行为异常,且相关血液学未见明显异常,病理学检查未见相关实施例化合物毒性作用,说明本发明实施例化合物1、实施例化合物7安全性良好,动物能够安全耐受。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,凡是根据本发明精神实质所做的等效变化或修饰,都应涵盖本发明的保护范围之内。
Claims (23)
- 一种通式(Ⅱ)所示的化合物或其可药用盐或同位素衍生物,
其中R1为-C1-3氘代烷基;R2为-C3-6环烷基,其中所述的-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代;R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;R4为5-6元杂芳基或六至十元双环,其中所述的5-6元杂芳基任选地被Ra取代,所述的双环,环与环之间是稠合相连的,且至少有一个环是芳族环,所述的双环任选地被Rb取代;Ra为-H、卤素、-CN、-C1-3烷基、-C1-3烷氧基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基、-C1-3烷氧基或-C3-6环烷基任选地进一步被选自氢原子、-NH2、-CF3、-CN、-C1-3烷基、-C2-3烯基、-C2-3炔基、-C1-3烷氧基、-C1-3烷基氨基、-C(O)NH-C1-3烷基、-C3-6环烷基、4-6元杂环基或卤素中的一个或多个取代基所取代;Rb为-S(O)2-C1-3烷基或-S(O)NH-C1-3烷基; - 根据权利要求1所述的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-CD3;R2为取代或未被取代的环丙烷基;R3为-OCH3、-OCF3、-O-CH2CH3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-O-CH2CH2F、-O-CH2CH(CH3)2、-OCH(CH3)2或
- 根据权利要求1或2所述的化合物或其可药用盐或同位素衍生物,其特征在于,R4为
- 据权利要求1-3任一项所述的化合物或其可药用盐或同位素衍生物,其特征在于,Ra为-H、-F、-CN、-CHF2、甲基、乙基、丙基、三氟甲基、甲氧基、-CH2-CF3、-CH2-CN、-CH2-CCH、-CH2-OCH3、-CH2CH2-CF3、-CH2CH2-OCH3、-CH2CH2-NH2、-CH2CH2-NH-CH3、-CH(CH3)2、-CH2-C(O)NH-CH3、或环丙烷基;Rb为-S(O)2-CH3或-S(O)NH-CH3。
- 根据权利要求1~4任一项所述的一种通式(Ⅱ)所示的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-C1-3氘代烷基;R2为-C3-6环烷基,其中所述的-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代;R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;Ra为-H、-CN、-CF3、-C1-3烷基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基或-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代。
- 根据权利要求5所述的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-CD3;R2为取代或未被取代的环丙烷基;R3为-OCF3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-OCH(CH3)2或
- 根据权利要求5或6所述的化合物或其可药用盐或同位素衍生物,其特征在于,R4为
- 根据权利要求5-7任一项所述的化合物或其可药用盐或同位素衍生物,其特征在于,Ra为-H、-CN、-CHF2、甲基、乙基、三氟甲基、-CH(CH3)2或环丙烷基。
- 根据权利要求1~4任一项所述的一种通式(Ⅱ)所示的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-C1-3氘代烷基;R2为-C3-6环烷基;R3为卤素取代的C1-3烷氧基;R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;Ra为-H、-C1-3烷基、-C1-3卤代烷基、-C3-6环烷基或4-6元杂环基。
- 根据权利要求9所述的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-CD3;R2为环丙烷基;R3为-OCF3或-OCHF2。
- 根据权利要求9或10所述的化合物或其可药用盐或同位素衍生物,其特征在于,R4为任选被Ra取代5元杂芳基,所述杂芳基包含1、2、3或4个氮杂原子。
- 根据权利要求9-11任一项所述的化合物或其可药用盐或同位素衍生物,其特征在于,R4为Ra为-H、甲基、乙基、三氟甲基或环丙烷基。
- 根据权利要求1~4任一项所述的一种通式(Ⅱ)所示的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-C1-3氘代烷基;R2为-C3-6环烷基;R3为-C1-3烷基氧基或-C3-6环烷基氧基,其中所述的-C1-3烷基氧基或-C3-6环烷基氧基任选地进一步被选自氢原子、氘原子、-C1-3烷基和卤素中的一个或多个取代基所取代;R4为5-6元杂芳基,其中所述的5-6元杂芳基任选地被Ra取代;Ra为-H、-CN、-CF3、-C1-3烷基、-C3-6环烷基或4-6元杂环基,其中所述的-C1-3烷基或-C3-6环烷基任选地进一步被选自氢原子、-C1-3烷基和卤素中的一个或多个取代基所取代。
- 根据权利要求13所述的化合物或其可药用盐或同位素衍生物,其特征在于,R1为-CD3;R2为环丙烷基;R3为-OCF3、-O-CH2CF3、-OCHF2、-O-CH2CHF2、-OCH(CH3)2或
- 根据权利要求13或14所述的化合物或其可药用盐或同位素衍生物,其特征在于,R4为
- 据权利要求12-15任一项所述的化合物或其可药用盐或同位素衍生物,其特征在于,Ra为-H、-CN、-CHF2、甲基、乙基、三氟甲基、-CH(CH3)2或环丙烷基。
- 根据权利要求1-4任一项所述的化合物或其可药用盐或同位素衍生物,其特征在于,所述化合物选自如下化合物或其可药用盐或同位素衍生物:
- 权利要求1-17中任一项所述式II所示化合物的制备方法,其特征在于,包含方案一或方案二的步骤,方案一:
方案二:
化合物IIa硼酸化后和R4X反应得到化合物IId,或化合物IIa和R4H直接反应得到化合物IId;化合物IId和化合物IIe反应得到化合物IIf;化合物IIf和R2C(O)NH2反应得到化合物II;其中X为Br或I,R1、R2、R3和R4如权利要求1-17中任一项所述。 - 一种药物组合物,其特征在于,包括治疗有效量的权利要求1-17中任一项的式II所示化合物或其可药用盐或同位素衍生物,以及任选一种或多种药学上可接受的载剂和/或稀释剂。
- 根据权利要求1-17任一项所述的式II所示化合物或其可药用盐或同位素衍生物,或者根据权利要求19所述的药物组合物在制备用于预防和/或治疗TYK2介导的疾病的药 物中的用途。
- 根据权利要求20所述的用途,其特征在于,所述TYK2介导的疾病包括炎性疾病或自身免疫性疾病。
- 根据权利要求20所述的用途,其特征在于,所述炎性疾病和自身免疫疾病为银屑病、炎症性肠病或红斑狼疮。
- 治疗TYK2介导的疾病的方法,包括给需要这种治疗的患者施用治疗有效量的权利要求1-17中任一项所述的式II所示化合物或其可药用盐或同位素衍生物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210639258.0 | 2022-05-31 | ||
CN202210639258 | 2022-05-31 | ||
CN202211224843.0 | 2022-10-09 | ||
CN202211224843 | 2022-10-09 | ||
CN202310073896 | 2023-02-07 | ||
CN202310073896.5 | 2023-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023231997A1 true WO2023231997A1 (zh) | 2023-12-07 |
Family
ID=89026910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/096975 WO2023231997A1 (zh) | 2022-05-31 | 2023-05-30 | 一种哒嗪类化合物、其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023231997A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024165000A1 (zh) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104159891A (zh) * | 2012-01-10 | 2014-11-19 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
CN104884454A (zh) * | 2012-11-08 | 2015-09-02 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物 |
CN113773262A (zh) * | 2020-06-09 | 2021-12-10 | 江苏先声药业有限公司 | 哒嗪类化合物 |
-
2023
- 2023-05-30 WO PCT/CN2023/096975 patent/WO2023231997A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104159891A (zh) * | 2012-01-10 | 2014-11-19 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
CN104884454A (zh) * | 2012-11-08 | 2015-09-02 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物 |
CN113773262A (zh) * | 2020-06-09 | 2021-12-10 | 江苏先声药业有限公司 | 哒嗪类化合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024165000A1 (zh) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110337294B (zh) | 作为cftr增效剂的吡咯并嘧啶 | |
JP6955482B2 (ja) | Tnfアルファの修飾因子として有用なヘテロ環化合物 | |
KR102057877B1 (ko) | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 | |
CN104703987B (zh) | 具有咪唑并吡嗪酮骨架的pde9抑制剂 | |
CN113493447A (zh) | Glp-1受体激动剂 | |
EP4248973A2 (en) | Pyridazinone compounds and uses thereof | |
CN101939053A (zh) | 可溶性的鸟苷酸环化酶活化剂 | |
TW201940166A (zh) | 作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途 | |
CN111094265B (zh) | 吡唑衍生化合物及其用途 | |
US11020380B2 (en) | Therapeutic compounds | |
CA3047812A1 (en) | Tetrazole containing compounds | |
WO2020192650A1 (zh) | 酰胺类化合物制备方法及其在医药领域的应用 | |
WO2023231997A1 (zh) | 一种哒嗪类化合物、其制备方法和用途 | |
CN111196804A (zh) | TGF-βR1抑制剂及其应用 | |
TWI724753B (zh) | 醯胺基橋連雜環類化合物、及其組合物與應用 | |
EP2619197B1 (en) | Oxadiazole inhibitors of leukotriene production | |
US20230303534A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
WO2022213980A1 (zh) | Tyk2抑制剂及其用途 | |
CN117396473A (zh) | 血浆激肽释放酶的咪唑并吡啶基抑制剂 | |
KR20210022646A (ko) | 시아노트리아졸 화합물 및 이의 용도 | |
JP6219817B2 (ja) | フェニルキサンテン誘導体 | |
CN118338902A (zh) | 吡咯并[2,3-b]吡啶PGDH抑制剂及制备和使用方法 | |
CN111712503A (zh) | 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 | |
CN107428682B (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
WO2022233442A1 (en) | 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23815176 Country of ref document: EP Kind code of ref document: A1 |